
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39245747
71904
10.1038/s41598-024-71904-3
Article
Development and validation of nomograms for predicting cardiovascular disease risk in patients with prediabetes and diabetes
Li Zhao
Kang Seamon
Kang Hyunsik hkang@skku.edu

https://ror.org/04q78tk20 grid.264381.a 0000 0001 2181 989X College of Sport Science, Sungkyunkwan University, 2066 Seoburo, 16419 Jangan-gu, Suwon Republic of Korea
8 9 2024
8 9 2024
2024
14 2090921 6 2024
2 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
This study aimed to develop and validate distinct nomogram models for assessing CVD risk in individuals with prediabetes and diabetes. In a cross-sectional study design, we examined data from 2294 prediabetes and 1037 diabetics who participated in the National Health and Nutrition Examination Survey, which was conducted in the United States of America between 2007 and 2018. The dataset was randomly divided into training and validation cohorts at a ratio of 0.75–0.25. The Boruta feature selection method was used in the training cohort to identify optimal predictors for CVD diagnosis. A web-based dynamic nomogram was developed using the selected features, which were validated in the validation cohort. The Hosmer–Lemeshow test was performed to assess the nomogram's stability and performance. Receiver operating characteristics and calibration curves were used to assess the effectiveness of the nomogram. The clinical applicability of the nomogram was evaluated using decision curve analysis and clinical impact curves. In the prediabetes cohort, the CVD risk prediction nomogram included nine risk factors: age, smoking status, platelet/lymphocyte ratio, platelet count, white blood cell count, red cell distribution width, lactate dehydrogenase level, sleep disorder, and hypertension. In the diabetes cohort, the CVD risk prediction nomogram included eleven risk factors: age, material status, smoking status, systemic inflammatory response index, neutrophil-to-lymphocyte ratio, red cell distribution width, lactate dehydrogenase, high-density lipoprotein cholesterol, sleep disorder, hypertension, and physical activity. The nomogram models developed in this study have good predictive and discriminant utility for predicting CVD risk in patients with prediabetes and diabetes.

Keywords

Cardiovascular disease
Prediabetes
Diabetes
Nomogram
Risk assessment
Subject terms

Biomarkers
Endocrinology
Health care
Medical research
Risk factors
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcCardiovascular diseases (CVDs), including ischemic heart disease and stroke, are the leading causes of death worldwide. An estimated 20.5 million people died from CVDs in 2021, accounting for roughly one-third of all global deaths and becoming the leading cause of premature noncommunicable disease mortality, particularly in low- and middle-income countries1. While CVD is also the leading cause of death among diabetic patients, both diabetes and prediabetes are independent risk factors for CVD2, indicating the clinical significance of CVD in patients with prediabetes and diabetes.

The National Diabetes Statistics Report for 2020 estimates that 34.1 million Americans aged ≥ 18 years (13.0% of US adults) have diabetes, with approximately 26.8 million diagnosed and 7.3 million undiagnosed (source: https://www.cdc.gov/diabetes/php/data-research/index.html). Prediabetes, defined as elevated blood glucose levels but below the diabetic threshold, refers to a prelude to diabetes or a condition that indicates a high risk of developing diabetes. Although the annual conversion rate from prediabetes to diabetes varies from 5 to 15%, depending on population characteristics and prediabetes definitions used, up to 70% of people with prediabetes are expected to develop diabetes3. Because prediabetes and diabetes can quickly turn into CVD, a lot of progress has been made in the last few years in the use of drugs to treat diabetes. New drugs like sodium-glucose cotransporter-2 inhibitors and glucose-like peptide-1 receptor agonists not only help control blood sugar better but also lower the risk of cardiovascular events4. These developments highlight the changing landscape of diabetes care and the significance of taking these factors into account when assessing CVD risk in diabetic populations.

While diabetes and prediabetes are two distinct risk factors for CVD, they share some etiological factors4. Diabetes causes an increase in reactive oxygen species (ROS), promoting prothrombotic and inflammatory responses, hastening atherosclerosis, and developing macrovascular complications4. Consequently, individuals with diabetes have a high risk of developing CVD, such as myocardial infarction, stroke, and peripheral artery disease5. At the same time, diabetes affects patients with various CVDs6, Similarly, prediabetes is associated with an increased risk of diabetes and CVD in the general population7 and in patients with atherosclerotic CVD8. Despite having a pathology similar to that of diabetes, cardiovascular complications caused by prediabetes are frequently overlooked and undertreated.

CVD is a clinical disorder in which lifestyle choices, genetic predispositions, comorbid conditions, and inflammatory responses converge to affect cardiac and circulatory health. Demographic and socioeconomic variables, such as age, marital status, educational attainment, and income bracket, are closely related to CVD prevalence9–11. The condition further correlates with unhealthy habits, including sedentariness, physical inactivity, and excessive weight, along with detrimental practices, such as heavy smoking and alcohol consumption. Comorbidities, such as hypertension, sleep disorders, and gastrointestinal diseases, are associated with cardiovascular health12,13. Moreover, inflammation is increasingly recognized as a pivotal contributor to CVD pathogenesis. In contrast, lifestyle modifications, including regular physical activity, interruption of prolonged sedentary periods, and nutritious diet, exhibit protective and therapeutic benefits against diabetes and CVD, reducing recurrence and aiding health restoration14.

Predicting the risk of CVD in patients with diabetes and prediabetes can enable more effective management of these patients by tailoring therapy to those who are most at risk. However, understanding the multifactorial nature of CVD in patients with prediabetes and diabetes requires a nuanced and thorough approach. Therefore, we aimed to develop and validate a Boruta algorithm-based nomogram15,16 for a straightforward assessment of CVD risk in prediabetes and diabetes conditions. This tool is intended to facilitate prompt identification of risk factors, thereby streamlining early intervention strategies and rehabilitation efforts. However, the incorporation of risk factors into a single numerical estimate of CVD risk in patients with prediabetes and diabetes has not been thoroughly studied or validated. Our study was predicated on developing and validating two distinct nomogram models subsequently for accurately evaluating the potential for CVD within separate cohorts of prediabetes and diabetes survivors, enabling a more targeted approach to their clinical management.

Methods

Study design

This cross-sectional study used data from the National Health and Nutrition Examination Survey (NHANES), a nationally representative database that collects information on the health and nutritional status of adults and children living in the United States of America. The NHANES database is updated annually by the National Center for Health Statistics of the Centers for Disease Control and Prevention. The NHANES uses a sophisticated multistage probability sampling framework to meticulously select approximately 5000 participants every 2 years who undergo comprehensive personal interviews and detailed physical examinations. In this study, we methodically curated data from six survey cycles conducted between 2007 and 2018. After data cleaning and interpolation, we obtained the final data for analysis, which included 2294 prediabetic and 1037 diabetic survivors with CVD prevalence rates of 14.8% and 28.2%, respectively.

Data interpolation

This study addressed the inherent complexities of the NHANES, which employed a stratified multi-stage probability sampling design. To accurately handle the weighted nature of the NHANES database, our analyses were performed using the Jomo package, a comprehensive suite within the R statistical framework designed specifically for multilevel joint modeling and multiple imputation. We implemented a survey-weighted generalized linear model using a Bayesian model-fitting paradigm to account for the nuanced data structure for our interpolation efforts. A Gibbs sampling strategy was meticulously applied to generate imputed datasets, allowing the production of five distinct imputed datasets after a 1000-iteration burn-in period. This rigorous computational process was critical to ensure stochastic independence among the imputed sets, a necessary criterion for validating our subsequent statistical inference.

Participant consolidation and cohort assignment

As shown in Fig. 1, the initial aggregation yielded a comprehensive cohort of 59,842 participants (15,004 with prediabetes and 6384 with diabetes) after excluding those without complete CVD data (12,710 with prediabetes and 5347 with diabetes). This resulted in an eligible cohort of 2294 and 1037 patients with prediabetes and diabetes, respectively, for further analysis. A randomized allocation protocol was used to develop a predictive model with robust validation mechanisms. Three-quarters of the dataset was divided into a training cohort, allowing for the extensive development and refinement of predictive algorithms. The remaining quarter was designated as the validation cohort to ensure that the predictive capacity of the model was rigorously tested against an independent sample, thereby increasing the reliability and validity of the study results.Fig. 1 Selection of study participants.

Variables

@@@Definition of prediabetes, diabetes survivors, and CVD.

Prediabetes was defined as the presence of any of the following conditions: a fasting plasma glucose level of 100–125 mg/dL, a glycated hemoglobin (HbA1c) level of 5.7–6.4%, physician-diagnosed prediabetes, impaired fasting glucose, impaired glucose tolerance, borderline diabetes, or blood sugar level higher than normal but not high enough to be classified as diabetes or sugar diabetes17. Diabetes was defined as the occurrence of any of the following conditions: fasting glucose level of ≥ 126 mg/dL, HbA1C level of ≥ 6.5%, physician-diagnosed diabetes, injecting insulin, or intake of antidiabetic pills to lower blood sugar18. Patients with CVD were defined as those who had survived any type of diagnosed heart disease, such as stroke, congestive heart failure, coronary heart disease, angina/angina pectoris, or heart attack19.

@@@Definition of risk factors

The risk factors included in the study were comorbidities, health behaviors, complete blood count, and sociodemographic factors. The comorbidities included sleep disorders, stomach and intestinal illnesses, and hypertension. Answering "YES" to the following question indicated sleeping disorders: Have you ever told your doctor or another healthcare professional that you have trouble sleeping? Answering "YES" to the following question indicated stomach or intestinal illness: Have you had stomach or intestinal illness with vomiting or diarrhea within the last 30 days? Answering "YES" to the following question indicated hypertension: Have you ever been told by a doctor or another health professional that you have hypertension or high blood pressure?

Health behaviors included physical activity, sedentary time, body mass index (i.e., underweight, normal, overweight, obese, and morbidly obese), smoking (smokers vs. nonsmokers), heavy alcohol consumption, sleep duration, and oral health. The International Physical Activity Questionnaire was used to assess daily physical activities such as vigorous work or recreational activity (VPA), moderate work or recreational activity (MPA), and light physical activity (LPA) such as walking. The weekly physical activity volume was calculated as the metabolic equivalent of task (METs)-min per week by multiplying the MET value given to the VPA (8.0 METs), MPA (4.0 METs), and LPA (3.0 METs) by the minutes the activity was carried out, and again by the number of days that each activity was undertaken. Physical activity volume was classified as low (< 500 MET-min/week), moderate (500–1000 MET-min/week), or high (> 1000 MET-min/week)20.

Fasting blood samples were collected at NHANES mobile examination sites and sent to the National Center for Environmental Health and the Centers for Disease Control and Prevention. A Beckman Coulter MAXM instrument (UniCel DxH 800 analyzer, Beckman Coulter, Inc., Brea, California, United States) was used to perform a complete blood count (CBC), with CBC parameters calculated by counting, sizing, automatic dilution, and mixing of samples. The systemic immune inflammation index (SII) was calculated as the product of the platelet and neutrophil counts divided by the lymphocyte count. The systemic inflammatory response index (SIRI) was calculated as the product of monocyte and neutrophil counts divided by lymphocyte count. Pan immune inflammation (PIV) was calculated as the product of platelet, neutrophil, and monocyte counts divided by the lymphocyte count. The neutrophil/lymphocyte ratio (NLR) was calculated as the number of neutrophils divided by the number of lymphocytes. The platelet/lymphocyte ratio (PLR) was calculated by dividing the platelet count by the lymphocyte count. The monocyte/lymphocyte ratio (MLR) was calculated by dividing the monocyte count by the lymphocyte count. The aggregate index of systemic inflammation (AISI) was calculated by dividing the neutrophil, platelet, and monocyte counts by the lymphocyte count. The triglyceride-glucose index (TyG) was calculated using Ln [fasting triglycerides (mg/dl) × fasting blood glucose (mg/dl)/2]). White blood cell count, hematocrit, red cell distribution width, hemoglobin, mean platelet volume, albumin, alanine aminotransferase, aspartate aminotransferase, total bilirubin, uric acid, osmolality, lactate dehydrogenase, total cholesterol, high-density lipoprotein cholesterol (HDLC), and low-density lipoprotein cholesterol (LDLC) were all included. Detailed procedures for specimen collection and processing are available on the NHANES website (https://www.cdc.gov/nchs/nhanes/index.htm).

Finally, social and demographic factors included sex (female vs. male), race (non-Hispanic white people, non-Hispanic black people, Mexican Americans, other Hispanics, and other races), education (college graduate or above, less than college), marital status (married/living with partner, widowed/divorced/separated, never married), and family income to poverty ratio (> 4, 1–4, < 1).

Statistical analysis

Normally distributed data are represented using means and standard deviations, whereas non-normally distributed data are represented using medians and quartiles. Categorical variables are represented as counts and percentages (%), and group comparisons were performed using the chi-square test for categorical variables. Pearson’s correlation analysis was performed for all the variables.

We then used the Boruta feature selection algorithm to identify optimal predictors for CVD diagnosis. Multicollinearity was detected by calculating the variance inflation factor (VIF) and was removed by sequentially excluding variables with the largest VIF from the dataset until all variables had a VIF of < 4. The selected features were used to develop a web-based nomogram to assess the CVD risk. In the nomogram model, each risk factor was assigned a point based on the odds ratio (OR). The probability of CVD risk was calculated by adding the total score for each risk factor and plotting it against a total-point scale. The goodness of fit and stability of the nomogram model was tested using the Hosmer–Lemeshow test. The accuracy of the nomogram model was evaluated using the internal bootstrap method that involved 1,000 repeated random samples with replacements. The discriminative ability and predictive performance of the nomogram model were evaluated using receiver operating characteristic (ROC) curves and calibration plots. The clinical prediction utility of the model was evaluated using decision curve analysis (DCA) and clinical impact curves (CIC). All statistical analyses and graph visualizations were performed using R-4.3.2 for Windows.

Results

Descriptive statistics of study participants

Overall, this study enrolled 2,294 individuals with prediabetes and 1,037 individuals with diabetes who participated in the 2007–2018 NHANES. Patients with prediabetes were randomly assigned to either a training cohort (n = 1,719) or a validation cohort (n = 575). Similarly, patients with diabetes were randomly assigned to either a training cohort (n = 777) or a validation cohort (n = 260). Considering prediabetes, the prevalence of CVD was 14.8%, with 14.8% in the training cohort (n = 255) and 14.9% in the validation cohort (n = 86). Considering only diabetes, the prevalence of CVD was 28.2%, with 28.1% in the training cohort (n = 219) and 28.1% in the validation cohort (n = 73).

The descriptive statistics of prediabetes and diabetes cohorts according to the CVD status are presented in Table 1. Regarding demographic characteristics, individuals with prediabetes with CVD were older, more likely to be male and non-Hispanic white, had a lower income, were less likely to be married and living with a partner, were more likely to be obese, drank less, smoked less, had poor oral health, had less sleep time, had higher rates of sleep disorders, hypertension, and stomach intestinal illness, were less physically active, and were more sedentary than their CVD-free counterparts. Individuals with diabetes and CVD were older, predominantly non-Hispanic white, less likely to be married or living with a partner, more likely to be former smokers, less likely to be physically active, more likely to be sedentary, had less sleep time, and had higher rates of hypertension and sleep disorders than their CVD-free counterparts.Table 1 Descriptive statistics of study participants by prediabetes and diabetes status.

Factors	Level	Prediabetes cohort
(n = 2,294)	P value	Diabetes cohort
(n = 1,037)	P value	
Train set	Validation set	Train set	Validation set	
(n = 1,719)	(n = 575)	(n = 777)	(n = 260)	
CVD (%)	No	1464 (85.17)	489 (85.04)	0.9971	558 (71.81)	187 (71.92)	1.0000	
Yes	255 (14.83)	86 (14.96)	219 (28.19)	73 (28.08)	
Age (%)	18–40	349 (20.30)	118 (20.52)	0.6510	58 (7.46)	29 (11.15)	0.1013	
41–65	812 (47.24)	282 (49.04)	384 (49.42)	114 (43.85)	
65 + 	558 (32.46)	175 (30.43)	335 (43.11)	117 (45.00)	
Sex (%)	Female	830 (48.28)	272 (47.30)	0.7198	391 (50.32)	124 (47.69)	0.5077	
Male	889 (51.72)	303 (52.70)	386 (49.68)	136 (52.31)	
Race (%)	Non-Hispanic White	837 (48.69)	275 (47.83)	0.6632	308 (39.64)	110 (42.31)	0.4229	
Mexican American	274 (15.94)	97 (16.87)	141 (18.15)	44 (16.92)	
Other Hispanic	191 (11.11)	57 (9.91)	83 (10.68)	28 (10.77)	
Non-Hispanic Black	343 (19.95)	126 (21.91)	227 (29.21)	67 (25.77)	
Other Race	74 (4.30)	20 (3.48)	18 (2.32)	11 (4.23)	
Education attainment (%)	College graduate or above	305 (17.74)	107 (18.61)	0.6851	83 (10.68)	28 (10.77)	1.0000	
Less than college	1414 (82.26)	468 (81.39)	694 (89.32)	232 (89.23)	
Material status (%)	Married/live with partner	1040 (60.50)	346 (60.17)	0.9169	450 (57.92)	151 (58.08)	0.6504	
Widowed/divorced/separated	474 (27.57)	163 (28.35)	257 (33.08)	81 (31.15)	
Never married	205 (11.93)	66 (11.48)	70 (9.01)	28 (10.77)	
PIR (%)	More than 4	429 (24.96)	136 (23.65)	0.7393	142 (18.28)	50 (19.23)	0.8612	
1–4	972 (56.54)	326 (56.70)	456 (58.69)	154 (59.23)	
Less than 1	318 (18.50)	113 (19.65)	179 (23.04)	56 (21.54)	
BMI (%)	Normal weight(18–15)	383 (22.28)	127 (22.09)	0.2765	104 (13.38)	32 (12.31)	0.7547	
Overweight(25–30)	616 (35.83)	205 (35.65)	220 (28.31)	67 (25.77)	
Obese(30–35)	425 (24.72)	126 (21.91)	212 (27.28)	78 (30.00)	
Morbidly obese(35 +)	295 (17.16)	117 (20.35)	241 (31.02)	83 (31.92)	
Alcohol status (%)	Non-drinker	804 (46.77)	255 (44.35)	0.3367	380 (48.91)	127 (48.85)	1.0000	
Drinker	915 (53.23)	320 (55.65)	397 (51.09)	133 (51.15)		
Smoking status (%)	Never smoker	839 (48.81)	273 (47.48)	0.0596	361 (46.46)	132 (50.77)	0.4837	
Former smoker	487 (28.33)	190 (33.04)	272 (35.01)	84 (32.31)	
Current smoker	393 (22.86)	112 (19.48)	144 (18.53)	44 (16.92)	
SII (%)	Q1	444 (25.83)	131 (22.78)	0.2762	200 (25.74)	60 (23.08)	0.4296	
Q2	435 (25.31)	137 (23.83)	193 (24.84)	66 (25.38)	
Q3	417 (24.26)	156 (27.13)	199 (25.61)	60 (23.08)	
Q4	423 (24.61)	151 (26.26)	185 (23.81)	74 (28.46)	
SIRI (%)	Q1	445 (25.89)	129 (22.43)	0.2069	193 (24.84)	67 (25.77)	0.6916	
Q2	431 (25.07)	144 (25.04)	198 (25.48)	61 (23.46)	
Q3	430 (25.01)	142 (24.70)	198 (25.48)	61 (23.46)	
Q4	413 (24.03)	160 (27.83)	188 (24.20)	71 (27.31)	
PIV (%)	Q1	451 (26.24)	123 (21.39)	0.0758	197 (25.35)	63 (24.23)	0.4208	
Q2	421 (24.49)	152 (26.43)	198 (25.48)	61 (23.46)	
Q3	432 (25.13)	141 (24.52)	198 (25.48)	61 (23.46)	
Q4	415 (24.14)	159 (27.65)	184 (23.68)	75 (28.85)	
NLR (%)	Q1	451 (26.24)	125 (21.74)	0.1966	194 (24.97)	66 (25.38)	0.5067	
Q2	423 (24.61)	148 (25.74)	201 (25.87)	58 (22.31)	
Q3	422 (24.55)	152 (26.43)	198 (25.48)	64 (24.62)	
Q4	423 (24.61)	150 (26.09)	184 (23.68)	72 (27.69)	
PLR (%)	Q1	452 (26.29)	123 (21.39)	0.1224	194 (24.97)	66 (25.38)	0.6844	
Q2	423 (24.61)	149 (25.91)	202 (26.00)	58 (22.31)	
Q3	418 (24.32)	155 (26.96)	190 (24.45)	68 (26.15)	
Q4	426 (24.78)	148 (25.74)	191 (24.58)	68 (26.15)	
MLR (%)	Q1	447 (26.00)	128 (22.26)	0.2547	195 (25.10)	68 (26.15)	0.2249	
Q2	446 (25.95)	148 (25.74)	208 (26.77)	53 (20.38)	
Q3	415 (24.14)	145 (25.22)	190 (24.45)	71 (27.31)	
Q4	411 (23.91)	154 (26.78)	184 (23.68)	68 (26.15)	
AISI (%)	Q1	451 (26.24)	123 (21.39)	0.0758	197 (25.35)	63 (24.23)	0.4208	
Q2	421 (24.49)	152 (26.43)	198 (25.48)	61 (23.46)	
Q3	432 (25.13)	141 (24.52)	198 (25.48)	61 (23.46)	
Q4	415 (24.14)	159 (27.65)	184 (23.68)	75 (28.85)	
Platelet (%)	Q1	439 (25.54)	135 (23.48)	0.7892	203 (26.13)	57 (21.92)	0.2706	
Q2	425 (24.72)	149 (25.91)	200 (25.74)	60 (23.08)	
Q3	429 (24.96)	147 (25.57)	190 (24.45)	70 (26.92)	
Q4	426 (24.78)	144 (25.04)	184 (23.68)	73 (28.08)	
White blood cell (%)	Q1	449 (26.12)	129 (22.43)	0.1502	199 (25.61)	68 (26.15)	0.6707	
Q2	418 (24.32)	163 (28.35)	213 (27.41)	63 (24.23)	
Q3	438 (25.48)	150 (26.09)	180 (23.17)	59 (22.69)	
Q4	414 (24.08)	133 (23.13)	185 (23.81)	70 (26.92)	
Hematocrit (%)	Q1	440 (25.60)	141 (24.52)	0.9390	190 (24.45)	70 (26.92)	0.2775	
Q2	433 (25.19)	143 (24.87)	203 (26.13)	63 (24.23)	
Q3	423 (24.61)	144 (25.04)	204 (26.25)	56 (21.54)	
Q4	423 (24.61)	147 (25.57)	180 (23.17)	71 (27.31)	
Red cell distribution width (%)	Q1	450 (26.18)	165 (28.70)	0.3409	248 (31.92)	71 (27.31)	0.3224	
Q2	457 (26.59)	132 (22.96)	165 (21.24)	58 (22.31)	
Q3	394 (22.92)	134 (23.30)	192 (24.71)	61 (23.46)	
Q4	418 (24.32)	144 (25.04)	172 (22.14)	70 (26.92)	
Hemoglobin (%)	Q1	454 (26.41)	144 (25.04)	0.5843	190 (24.45)	72 (27.69)	0.7194	
Q2	409 (23.79)	151 (26.26)	203 (26.13)	62 (23.85)	
Q3	451 (26.24)	141 (24.52)	201 (25.87)	68 (26.15)	
Q4	405 (23.56)	139 (24.17)	183 (23.55)	58 (22.31)	
Mean platelet volume (%)	Q1	449 (26.12)	161 (28.00)	0.7558	199 (25.61)	67 (25.77)	0.0868	
Q2	442 (25.71)	141 (24.52)	209 (26.90)	89 (34.23)	
Q3	411 (23.91)	130 (22.61)	176 (22.65)	54 (20.77)	
Q4	417 (24.26)	143 (24.87)	193 (24.84)	50 (19.23)	
Albumin (%)	Q1	532 (30.95)	179 (31.13)	0.7576	195 (25.10)	71 (27.31)	0.3710	
Q2	397 (23.09)	141 (24.52)	220 (28.31)	67 (25.77)	
Q3	431 (25.07)	146 (25.39)	179 (23.04)	70 (26.92)	
Q4	359 (20.88)	109 (18.96)	183 (23.55)	52 (20.00)	
Alanine aminotransferase (%)	Q1	463 (26.93)	160 (27.83)	0.3409	220 (28.31)	70 (26.92)	0.0580	
Q2	440 (25.60)	135 (23.48)	206 (26.51)	56 (21.54)	
Q3	407 (23.68)	125 (21.74)	163 (20.98)	75 (28.85)	
Q4	409 (23.79)	155 (26.96)	188 (24.20)	59 (22.69)	
Aspartate aminotransferase (%)	Q1	423 (24.61)	157 (27.30)	0.1932	240 (30.89)	80 (30.77)	0.3699	
Q2	509 (29.61)	144 (25.04)	174 (22.39)	51 (19.62)	
Q3	406 (23.62)	141 (24.52)	176 (22.65)	72 (27.69)	
Q4	381 (22.16)	133 (23.13)	187 (24.07)	57 (21.92)	
Total bilirubin (%)	Q1	641 (37.29)	196 (34.09)	0.2805	295 (37.97)	111 (42.69)	0.3357	
Q2	276 (16.06)	106 (18.43)	145 (18.66)	48 (18.46)	
Q3	455 (26.47)	145 (25.22)	181 (23.29)	61 (23.46)	
Q4	347 (20.19)	128 (22.26)	156 (20.08)	40 (15.38)	
Uric acid (%)	Q1	440 (25.60)	144 (25.04)	0.5619	207 (26.64)	69 (26.54)	0.2964	
Q2	449 (26.12)	157 (27.30)	179 (23.04)	72 (27.69)	
Q3	398 (23.15)	144 (25.04)	203 (26.13)	55 (21.15)	
Q4	432 (25.13)	130 (22.61)	188 (24.20)	64 (24.62)	
Osmolality (%)	Q1	521 (30.31)	171 (29.74)	0.9395	229 (29.47)	72 (27.69)	0.1993	
Q2	438 (25.48)	142 (24.70)	161 (20.72)	70 (26.92)	
Q3	399 (23.21)	135 (23.48)	208 (26.77)	60 (23.08)	
Q4	361 (21.00)	127 (22.09)	179 (23.04)	58 (22.31)	
Lactate dehydrogenase (%)	Q1	435 (25.31)	149 (25.91)	0.8637	216 (27.80)	56 (21.54)	0.0930	
Q2	434 (25.25)	136 (23.65)	193 (24.84)	60 (23.08)	
Q3	445 (25.89)	148 (25.74)	186 (23.94)	67 (25.77)	
Q4	405 (23.56)	142 (24.70)	182 (23.42)	77 (29.62)	
Total cholesterol (%)	Q1	440 (25.60)	145 (25.22)	0.0695	179 (23.04)	81 (31.15)	0.0746	
Q2	410 (23.85)	158 (27.48)	200 (25.74)	61 (23.46)	
Q3	450 (26.18)	122 (21.22)	197 (25.35)	60 (23.08)	
Q4	419 (24.37)	150 (26.09)	201 (25.87)	58 (22.31)	
HDL cholesterol (%)	Q1	432 (25.13)	146 (25.39)	0.9100	222 (28.57)	62 (23.85)	0.0233	
Q2	471 (27.40)	149 (25.91)	191 (24.58)	67 (25.77)	
Q3	402 (23.39)	136 (23.65)	162 (20.85)	76 (29.23)	
Q4	414 (24.08)	144 (25.04)	202 (26.00)	55 (21.15)	
LDL cholesterol (%)	Q1	433 (25.19)	154 (26.78)	0.8110	185 (23.81)	76 (29.23)	0.2174	
Q2	427 (24.84)	134 (23.30)	197 (25.35)	69 (26.54)	
Q3	432 (25.13)	141 (24.52)	198 (25.48)	54 (20.77)	
Q4	427 (24.84)	146 (25.39)	197 (25.35)	61 (23.46)	
TyG (%)	Q1	420 (24.43)	154 (26.78)	0.1880	186 (23.94)	74 (28.46)	0.1342	
Q2	429 (24.96)	144 (25.04)	195 (25.10)	64 (24.62)	
Q3	448 (26.06)	125 (21.74)	207 (26.64)	52 (20.00)	
Q4	422 (24.55)	152 (26.43)	189 (24.32)	70 (26.92)	
Teeth health (%)	Good	994 (57.82)	353 (61.39)	0.2424	422 (54.31)	137 (52.69)	0.7696	
Fair	410 (23.85)	119 (20.70)	183 (23.55)	67 (25.77)	
Poor	315 (18.32)	103 (17.91)	172 (22.14)	56 (21.54)	
Sleep disorder (%)	No	1266 (73.65)	431 (74.96)	0.5725	551 (70.91)	173 (66.54)	0.2105	
Yes	453 (26.35)	144 (25.04)	226 (29.09)	87 (33.46)	
Sleep duration (%)	8-12 h	131 (7.62)	39 (6.78)	0.7882	71 (9.14)	24 (9.23)	0.4451	
6-8 h	1274 (74.11)	432 (75.13)	553 (71.17)	194 (74.62)	
Less than 6 h	314 (18.27)	104 (18.09)	153 (19.69)	42 (16.15)	
Stomach intestinal illness (%)	No	1566 (91.10)	524 (91.13)	1.0000	705 (90.73)	237 (91.15)	0.9369	
Yes	153 (8.90)	51 (8.87)	72 (9.27)	23 (8.85)	
Hypertension (%)	No	944 (54.92)	320 (55.65)	0.7957	264 (33.98)	87 (33.46)	0.9392	
Yes	775 (45.08)	255 (44.35)	513 (66.02)	173 (66.54)	
Physical activity (%)	Vigorous	785 (45.67)	277 (48.17)	0.5359	232 (29.86)	94 (36.15)	0.1661	
Moderate	163 (9.48)	49 (8.52)	61 (7.85)	19 (7.31)	
Low	771 (44.85)	249 (43.30)	484 (62.29)	147 (56.54)	
Sedentary duration (%)	Q1	658 (38.28)	201 (34.96)	0.5582	271 (34.88)	83 (31.92)	0.2929	
Q2	259 (15.07)	93 (16.17)	193 (24.84)	70 (26.92)	
Q3	380 (22.11)	134 (23.30)	191 (24.58)	75 (28.85)	
Q4	422 (24.55)	147 (25.57)	122 (15.70)	32 (12.31)	
PLR poverty income ratio; BMI body mass ratio; SII systemic immune inflammation index; SIRI systemic inflammatory response index; PIV pan immune inflammation; NLR neutrophil/lymphocyte ratio; PLR platelet/lymphocyte ratio; MLR monocyte/lymphocyte ratio; AISI aggregate index of systemic inflammation; HDL high-density lipoprotein; LDL low-density lipoprotein; TYG triglyceride-glucose index.

The CVD risk predictors in prediabetes and diabetes cohorts are presented in Table 2. In the prediabetes cohort, CVD risk factors included age, smoking status, MLR, platelets, WBCs, red cell distribution width, lactate dehydrogenase (LDH), sleep disorders, and hypertension. In the diabetes cohort, the CVD risk factors were age, smoking, marital status, SIRI, NLR, red blood cell distribution width, LDH, HDLC, sleep disorders, hypertension, and physical activity. Additionally, the heatmap in Fig. 2 shows that the association between the variables was similar in the prediabetes and diabetes cohorts.Table 2 Nomogram predictors score range by prediabetes and diabetes.

Prediabetes cohort	Diabetes cohort	
Predictors	Level	Score range	Predictors	Level	Score range	
Age	18–40	24	Age	18–40	25	
41–65	63	41–65	79	
65 + 	100	65 + 	100	
Smoking status	Never smoker	24	Material status	Married/living with a partner	25	
Current smoker	40	Widowed/divorced/separated	34	
Former smoker	40	Never married	49	
MLR	Q1	24	Smoking status	Never smoker	25	
Q2	25	Current smoker	39	
Q3	12	Former smoker	46	
Q4	35	SIRI	Q1	25	
Platelet	Q1	24	NLR	Q2	21	
Q2	18	Q3	19	
Q3	3	Q4	30	
Q4	0	Q1	25	
White blood cell	Q1	24	Red cell distribution width	Q2	22	
Q2	36	Q3	31	
Q3	45	Q4	40	
Q4	54	Q1	25	
Red cell distribution width	Q1	24	Lactate dehydrogenase	Q2	33	
Q2	23	Q3	43	
Q3	32	Q4	43	
Q4	34	Q1	25	
Lactate dehydrogenase	Q1	24	HDL cholesterol	Q2	21	
Q 2	33	Q3	31	
Q3	37	Q4	36	
Q4	46	Q1	25	
Sleep disorder	Yes	47	Sleep disorder	Q2	28	
No	24	Q3	8	
Hypertension	Yes	65	Q4	0	
No	24	Yes	46	
Hypertension	No	25	
Yes	47	
No	25	
Physical activity	Low	42	
Moderate	40	
Vigorous	25	

Fig. 2 The correlation between variables in the prediabetes and diabetes cohorts.

Determination of CVD risk factors

Figure 3 presents the outcomes of Boruta feature selection. The Boruta algorithm is a feature selection technique that uses the Random Forest algorithm. The algorithm generates shadow features from the original features and combines them into a random-forest model. During the selection process, if the importance of the original feature outweighs that of the shadow feature, the feature is considered confirmed. Eventually, the important feature is marked in green (“confirmed”) for further analyses, while the excluded features are marked in red (“rejected”) or blue (“tentative”). In our study, based on Boruta feature selection, age, smoking status, SII, SIRI, NLR, MLR, AISI, platelet count, white blood cell count, red cell distribution width, LDH, sleep disorders, and hypertension were chosen to develop a nomogram model for the prediabetes cohort (Fig. 3a). Age, material status, smoking status, SIRI, NLR, red cell distribution width, LDH, HDL cholesterol, sleep disorders, hypertension, and physical activity were selected to develop a nomogram model for the diabetes cohort (Fig. 3b).Fig. 3 Boruta algorithm feature selection.

Elimination of multicollinearity

After feature selection, multicollinearity was eliminated. Multicollinearity pertains to the degree of information sharing among variables, which poses a challenge in accurately identifying the individual effects of each independent variable on the dependent variable. We evaluated multicollinearity by calculating the VIF and eliminated it by removing the variables with the highest VIF one by one until all of them had a VIF < 4. We excluded SII, SIRI, NLR, and AISI from the prediabetes model because they all had a VIF < 4 (Supplemental Table 1). Subsequently, we developed a web-based dynamic nomogram using the selected features.

Goodness of fit testing

The Hosmer–Lemeshow (HL) test, a critical method for assessing goodness of fit, was used to evaluate the performance and robustness of the nomogram model21. This test assesses the concordance between observed outcomes and predictions by dividing the predicted probabilities into deciles and comparing the observed frequencies of events within these deciles to the expected frequencies calculated from the model. The HL test yielded p-values of 0.9364 and 0.9475 for the training and validation sets, respectively, in the pre-diabetes prediction model. Concurrently, the diabetes prediction model had p-values of 0.6157 and 0.7271 for the training and validation sets, respectively. These p-values are significantly higher than the conventional threshold of 0.05, indicating a lack of substantial evidence to reject the hypothesis of an adequate model fit. These findings support the commendable calibration of the models, confirming that the predicted probabilities of CVD risk closely match the observed outcomes across the various stages of diabetes.

Construction of nomograms for predicting CVD risk

Figure 4 shows the construction of nomograms for predicting the risk of CVD in the prediabetes and diabetes cohorts. Each predictor received a score ranging from 0 to 100 points. The total points for each variable were added, and a vertical line was drawn downward from the sum to represent the likelihood of CVD. A higher score indicated an increased risk of CVD for the post-prediabetes and diabetes cohorts. Each predictor had a different score range depending on its level. We created a web calculator to make it easier and more intuitive to predict CVD risk probability (Prediabetes prediction calculator: https://zhaol2022713269.shinyapps.io/dynnomapp-1/, Diabetes prediction calculator: https://zhaol2022713269.shinyapps.io/dynnomapp-2/).Fig. 4 Nomogram models for predicting the probability of cardiovascular disease (CVD) risk in the prediabetes and diabetes cohorts.

The area under the ROC (AUC) was used to determine the predictive performance for CVD risk in two nomogram models. The nomogram for the prediabetes cohort was effective in detecting CVD, with an AUC of 0.800 (95% confidence interval (CI): 0.780–0.818, p < 0.001), a sensitivity of 82.75%, and a specificity of 63.87% in the training cohort (Fig. 5a). The validation cohort maintained predictive strength, resulting in a higher AUC of 0.842 (95% CI 0.809–0.871, p < 0.001), a sensitivity of 89.53%, and a specificity of 68.30% (Fig. 5b). Similarly, the nomogram for the diabetes cohorts showed a significant AUC of 0.779 (95% CI 0.748–0.807, p < 0.001), with a sensitivity of 68.95%, and a specificity of 71.86% in the training set (Fig. 5c). The nomogram demonstrated a moderate but significant AUC of 0.728 (95% CI 0.669–0.781, p < 0.001) in the validation cohort, with a sensitivity of 80.82% and specificity of 60.43% (Fig. 5d).Fig. 5 Receiver operating characteristic (ROC) analyses of the predictive nomograms for cardiovascular disease (CVD) risk in the prediabetes (a-b) and diabetes cohorts (c-d).

Performance assessment of the nomogram for predicting CVD risk

Internal validation using 1,000 bootstrap samples revealed that the nomogram model for prediabetes had a C-index of 0.800 in the training cohort with a mean absolute error (MAE) of 0.017 (Fig. 6a). The nomogram model calibration curve in the training cohort showed acceptable calibration, with a Brier score of 0.107, indicating good calibration, with no difference between the actual and predicted probabilities. Internal validation with 1,000 bootstrap samples revealed that the nomogram model for prediabetes had a C-index of 0.863 in the validation cohort and an MAE of 0.03 (Fig. 6b). The nomogram calibration curve in the validation cohort showed acceptable calibration with a Brier score of 0.095, indicating that the predicted probabilities were closely aligned with the actual CVD rates. In parallel, the nomogram for diabetes performed admirably, as evidenced by a C-index of 0.779 and an MAE of 0.026 in the training cohort (Fig. 6c), indicating significant predictive congruence. This was further supported by a Brier score of 0.162, indicating robust calibration of the model. The validation cohort yielded a consistent C-index of 0.780 and a slightly higher MAE of 0.058 (Fig. 6d), with the calibration curve achieving a Brier score of 0.159, confirming the fidelity of the predicted probabilities to the actual CVD rates.Fig. 6 Calibration curves of the nomograms for predicting cardiovascular disease (CVD) risk in the prediabetes (a,b) and diabetes cohorts (c,d).

DCA was used to assess the clinical applicability of the nomogram for prediabetes (Fig. 7a). The DCA in the training cohort (green line) showed that when the threshold probability is between 1 and 84%, the developed nomogram can provide a greater net benefit than intervention or non-intervention. The DCA in the validation cohort (red line) showed that the developed nomogram could provide a greater net benefit than intervention or non-intervention when the probability falls between 1 and 96%. Parallel evaluation of the nomogram for diabetes confirmed this pattern of clinical relevance (Fig. 7b). In the training cohort, the nomogram (green line) outperformed intervention or non-intervention across threshold probabilities ranging from 1 to 91%. The DCA of the validation cohort (red line) confirmed the applicability of the monogram, providing an increased net benefit across the entire range of threshold probabilities considered, from 1 to 93%.Fig. 7 Decision curve analysis and clinical impact curves of the nomograms for predicting cardiovascular disease (CVD) risk in the prediabetes (a) and diabetes cohorts (b).

Finally, combustion ion chromatography analysis was used to stratify CVD risk. We discovered a similar phenomenon in prediabetes and diabetes cohorts at a low-risk level. The number of patients with CVD based on the nomogram model differed from that of the true CVD population in the training cohort (Figs. 8a,c). However, at the low-risk threshold, the number of patients with CVD predicted by the nomogram model was similar to that of the true CVD population in the validation cohort (Figs. 8b,d). At the high-risk threshold, the CIC curves were more closely aligned with those of the training and validation cohorts. Overall, our findings suggest that our nomogram model is more clinically useful for predicting CVD in prediabetes survivors than intervention or non-intervention.Fig. 8 Clinical impact curve analysis for probability stratification of cardiovascular disease (CVD) risk in the training (a–c) and validation cohorts (b–d).

Discussion

This population-based cross-sectional study aimed to develop and validate nomogram models for predicting CVD risk in patients with prediabetes and diabetes. The optimal predictors used in the nomograms were selected using the Boruta feature-selection algorithm. The fitness and robustness of the models were validated by conducting the HL test. The predicted outcomes of the nomograms were in good agreement with the observed outcomes, as supported by the calibration curves, ROC curve analyses, and C-index values. The C-index value of the nomogram was approximately 0.9 for prediabetes and 0.8 for diabetes. The DCA results showed that the nomograms developed in our study have clinically relevant values for improving predictive precision and guiding clinical decision-making regarding CVD risk in patients with prediabetes and diabetes.

Our study findings revealed that both the prediabetes and diabetes cohorts shared some risk factors for CVD, including age, smoking status, red blood cell distribution width, LDH, sleep disorders, and hypertension. We somewhat expected the current findings, given the prevalence of shared risk factors among individuals with prediabetes, diabetes, or CVD. Overall, prediabetes and diabetes can contribute to CVD via various macrovascular complications, such as proinflammation, endothelial dysfunction, stroke, myocardial dysfunction, congestive heart failure, peripheral vascular diseases, and others22,23.

Although we used data from the USA for our study, it is critical to acknowledge the potential variations in cardiovascular disease (CVD) risk factors across different populations, including those in China and Korea. Genetic predispositions, dietary habits, lifestyle factors, and ethnic groups may contribute to these differences. For example, the dietary habits prevalent in East Asian populations, which often include higher intakes of fish, vegetables, and soy products compared to the Western diet, may contribute to ethnic differences in cholesterol levels and hypertension24. Furthermore, smoking rates, a significant CVD risk factor, vary markedly between regions, with traditionally higher prevalence among East Asian men relative to their Western counterparts25. Additionally, genetic polymorphisms affecting lipid metabolism may contribute to ethnic differences in the susceptibility to CVD26. Finally, while traditional CVD risk factors like smoking, blood pressure, and total cholesterol predict risk across ethnic groups, they do not fully account for ethnic differences in CVD27,28, because there have been reports of ethnic differences in visceral adiposity, insulin resistance, diabetes, and novel risk markers such as CRP, adiponectin, and plasma homocysteine. As a result, a future study that takes ethnicity into account will help improve risk prediction models in people with prediabetes and diabetes, as well as create and test ethnicity-specific models for predicting CVD risk29.

When comparing our model to well-established CVD risk prediction tools30,31, it becomes evident that traditional risk factors like age, smoking status, blood pressure, cholesterol levels, and BMI are typically emphasized in these tools. Furthermore, adding new markers like PLR, SIRI, RDW, and LDH to our model is based on new evidence from recent studies32,33 and makes it more accurate than traditional models, especially in high-risk groups like diabetics, where metabolic dysregulation is key for cardiovascular outcomes. Additionally, our findings enhance our understanding of CVD risk by emphasizing the importance of inflammatory indices. This is consistent with recent literature, which emphasizes the importance of inflammation in cardiovascular outcomes. For example, the link between SII and CVD has been extensively studied, highlighting the prognostic value of inflammatory markers in predicting cardiovascular events34,35.

Our CVD risk prediction nomograms have important practical implications in clinical settings. Compared to existing risk assessment tools recommended by the American Diabetes Association (ADA) and the American Heart Association (AHA)36, our model offers enhanced capabilities for early identification and personalized risk stratification of cardiovascular disease in patients with prediabetes and diabetes. By incorporating both traditional and novel risk factors, our model is consistent with the growing body of evidence supporting the inclusion of inflammatory and hematological markers in risk stratification frameworks. This comprehensive approach improves predictive accuracy while also aligning with the current trend toward more integrative and patient-centered care. Our nomogram's use in a variety of clinical settings may enable more effective prevention strategies and optimized therapeutic interventions for those at high risk of CVD, ultimately leading to better long-term cardiovascular health outcomes.

Currently, there are ten classes of orally available pharmacological agents to treat type-2 diabetes mellitus. They include sulfonylureas, meglitinides, metformin, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase IV inhibitors, bile acid sequestrants, dopamine agonists, sodium-glucose transport protein 2 inhibitors, and oral glucagon-like peptide 1 receptor agonists37. All the medications have glucose-lowering effects as well as lipid-lowering effects via various mechanisms of action37. Some medications help to prevent the progression from prediabetes to diabetes and CVD38 and to reduce major adverse cardiovascular events in patients with prediabetes and diabetes, as well as new diabetes onset 39. In the larger context of diabetes treatment, recent years have seen significant advances that go beyond the development of new pharmacological agents. It includes novel approaches to personalized medicine, advancements in patient monitoring technologies, and the integration of multidisciplinary care teams, all of which help diabetic patients have better cardiovascular outcomes. For example, advances in continuous glucose monitoring systems40 and the use of artificial intelligence41,42 to personalize treatment regimens have improved glycemic control while reducing fluctuations that increase cardiovascular risk. Furthermore, studies have demonstrated that multidisciplinary care approaches, involving coordinated management by endocrinologists, cardiologists, and dietitians, enhance treatment adherence and risk factor management, including blood pressure and lipid levels43. People increasingly regard these non-pharmacological strategies as critical components of comprehensive diabetes care, supplementing the effects of medication. As a result, adopting a lifestyle that emphasizes a healthy diet and physical activity in addition to medications remains the foundation of management and can help prevent the progression from pre-diabetes to diabetes, as well as from diabetes to CVD44.

As we refine our understanding of these advances’ treatment in the diabetic population, it becomes essential to consider how each predictor contributes to the overall predictive model for CVD. By dissecting the impact of predictors in this study, we can better understand their roles and interactions within this evolving framework.

Our study findings show that age is associated with an increased risk of both prediabetes and diabetes and is an independent risk factor for CVD worldwide45. CVDs, including hypertension, ischemic heart disease, atrial fibrillation, and heart failure, become more common as the population gets older. Additionally, age is the most significant risk factor of sudden death due to arteriosclerotic heart disease46. As a result, many CVD risk prediction models have incorporated age as an independent risk factor47,48. Pathologically, aging results in ROS accumulated damage due to a decrease in the body's ability to scavenge them49. Aging is also associated with the gradual deterioration of homeostatic mechanisms50 and reparative capacities51, making older individuals especially vulnerable to the negative effects of chronic hyperglycemia, which is common in both prediabetes and diabetes. Prolonged exposure to high glucose levels promotes the production of advanced glycation end products, which worsens vascular damage by stiffening the collagen matrix and impairing nitric oxide-mediated vasodilation52.

Cigarette smoking is a leading cause of avoidable morbidity and mortality worldwide9. Our study findings show that the risk scores for current and former smokers are similar, which emphasizes the critical point that cessation lowers risk but does not eliminate the cumulative effect of previous smoking on vascular health53. Accordingly, previous studies have shown that even years after quitting, the vascular system retains the memory of smoking exposure, as evidenced by persistent endothelial dysfunction and a proatherogenic environment54. Additionally, current smoking poses an ongoing risk because it worsens endothelial dysfunction55, which is likely exacerbated by metabolic disorders such as prediabetes and diabetes conditions.

Red cell distribution width (RCDW) and LDH levels are risk factors for prediabetes, diabetes, and CVD. RCDW measures differences in erythrocyte volume and size and is an index of anemia because red blood cells carry oxygen from the lungs to every cell in the body. Thus, an increase in RCDW may indicate a broader state of hematological dysregulation56 and is linked to increased inflammatory reactions57, nutritional deficiencies58, and oxidative stress59, all of which are common in diabetes and prediabetes. Additionally, a substantial body of evidence suggests that an elevated RCDW value is linked to CVD conditions, such as acute myocardial infarction60, peripheral artery disease61, atrial fibrillation62, heart failure63, hypertension64, and ischemic cerebrovascular disease65.

LDH catalyzes the reduction and oxidation reactions between pyruvate and lactate, involving the transfer of electrons between the two species. Since LDH is normally found at low concentrations in the blood, elevated serum LDH has been used as a biomarker of CVD and arterial fibrillation in healthy Chinese individuals32, a biomarker of renal outcomes and CVD mortality in patients with diabetic kidney disease66, and a predictor of cardiac insufficiency in older patients with acute myocardial infarction67. Furthermore, as an inflammatory marker, LDH may be used as a biomarker for glucose monitoring in those with prediabetes and diabetes68,69. Taken together, high RDW and LDH values suggest a higher risk of prediabetes, diabetes, and CVD; however, it is unclear how they relate to the pathology of these conditions.

Sleep disorders and hypertension are important risk factors for CVD. Sleep problems have been linked to a higher risk of all-cause and specific CVD morbidity and mortality in the general population70,71 and patients with diabetes72,73. The adverse effects of sleep problems on CVD have been summarized in recent systematic reviews74 and systematic meta-analyses75. Several negative characteristics, such as inflammation, impaired glucose tolerance, hyperinsulinemia, and dyslipidemia, have been linked to the impact of sleep disorders on CVD risk in prediabetes and diabetes conditions76. Concurrently, it is well-established that hypertension is an additive risk factor for CVD in individuals with prediabetes and diabetes77. Poor glycemic control, oxidative stress, insulin resistance, and low-grade inflammation are metabolic complications that contribute to CVD risk associated with prediabetes and diabetes78. The mechanisms by which hypertension and diabetes contribute to CVD have been summarized in a previous review79.

Our findings showed that MLR, platelet count, and WBC count are unique predictors of CVD risk in the prediabetes cohort. In line with the current findings, a large body of evidence suggests that the MLR and WBC count are inflammatory markers that contribute to the pathology and progression of prediabetes, diabetes, or CVD. For example, MLR is a novel inflammatory biomarker associated with major complications of type 2 diabetes, such as diabetic neuropathy80, diabetic retinopathy81, diabetic kidney injury82, and diabetic foot ulcers83. MLR is also an independent predictor of major adverse cardiovascular and cerebrovascular events in patients with coronary artery disease who underwent percutaneous coronary intervention84. In middle-aged and older Chinese adults, elevated WBC count is associated with obesity-related metabolic complications, such as impaired glucose tolerance and elevated HbA1c levels85. In a 10-year longitudinal community-based Korean cohort study of non-obese adults, a high WBC count predicted the development of type 2 diabetes86. This was also linked to a higher risk of coronary heart disease in a Mendelian randomization study using data from a genome-wide association studies (GWAS) dataset of heart failure involving 47,309 cases and 930,014 controls87. Platelet-induced hyper-aggregation is likely to increase the risk of CVDs in patients with altered glucose homeostasis, including both prediabetes and diabetes88,89. Therefore, the inverse relationship between platelet counts and CVD risk in the prediabetes cohort in this study is unforeseen and has not been elucidated. It remains to be confirmed in future studies.

Additionally, our findings showed that marital status, SIRI score, NLR, HDL-C, and physical inactivity were CVD risk factors specific to the diabetes cohort. Consistent with current findings, the risk factors unique to diabetes are well-known risk factors for CVD. For example, marital status is a sociodemographic risk factor for diabetes and CVD. Living alone, such as being separated and/or being divorced or widowed, is linked to an increased risk of morbidity90 and mortality in those with diabetes91 and CVD92,93. Collectively, the findings from current and previous studies suggest that marital status may influence the relationship between diabetes and CVD94.

HDLC has a protective effect against CVD95 because of its role in reverse cholesterol transport96,97 and its anti-inflammatory properties98,99. Individuals with diabetes show reduced HDLC and impaired anti-inflammatory capacities. In a diabetic environment with insulin resistance, dyslipidemia, and high oxidative stress due to elevated blood glucose or impaired glucose metabolism, HDLC glycation reduces anti-inflammatory capacity and cholesterol efflux from peripheral tissues. Glycation reduces sphingosine-1-phosphate (S1P) in HDLC. Several studies have indicated that in diabetes, not only the quantity but also the quality of HDL cholesterol is critical100,101; glycated or otherwise modified forms of HDL may be less effective or even pro-inflammatory102,103. Moreover, diabetes can alter lipid metabolism, leading to a complex interplay between HDL levels and the risk of CVD.

Physical inactivity is associated with insulin resistance, dyslipidemia, and a pro-inflammatory state, which serve as harbingers for cardiovascular events104,105. Diabetes, a condition characterized by metabolic disturbances, intensifies the negative effects of low physical activity levels. Failure to engage in adequate physical activity may potentiate the already heightened risk of cardiovascular complications, as physical inactivity itself can lead to worsening insulin sensitivity and endothelial dysfunction and escalate the risk for thrombosis106,107. By contrast, physical activity, with its myriad physiological benefits, is the cornerstone for promoting cardiovascular health. Regular exercise modulates glucose metabolism, improves endothelial function, and decreases inflammation, and all these activities collectively reduce the risk of CVDs108–111. Clinical trials and population studies have consistently demonstrated the benefits of regular physical activity for diabetes management and CVD risk reduction109,112,113. The Diabetes Prevention Program (DPP) and subsequent follow-up studies have shown that lifestyle interventions, including physical activity, significantly reduce the incidence of cardiovascular events in individuals with diabetes114–116.

This study had some limitations. First, the cross-sectional nature of the study limits any causal relationship between the risk factors included in the models and CVD. Therefore, to predict the risk of CVD in patients with prediabetes and diabetes, a prospective cohort study is required to ascertain how these risk factors interact. Second, external validation is necessary to determine the reproducibility and generalizability of the prediction model for new and different patients. Third, the NHANES database has missing data entries, which could compromise the accuracy and reliability of the model, although we adopted a suitable approach to data interpolation. Lastly, while traditional CVD risk factors like smoking, blood pressure, and total cholesterol predict risk across ethnic groups, they do not fully account for ethnic differences in CVD27,117,118 because there have been reports of ethnic differences in visceral adiposity, insulin resistance, diabetes, and novel risk markers such as CRP, adiponectin, and plasma homocysteine. Therefore, a future study considering those ethnicity differences will help make risk prediction models work better in people with prediabetes and diabetes, as well as help create and test models that are specific to race for predicting CVD risk29.

In conclusion, our study is a pioneering endeavor in developing and validating nomograms to predict CVD risk in patients with prediabetes and diabetes. This dual nomogram model encompasses an array of predictive factors, including social and demographic characteristics, comorbidities, health behaviors, metabolic profiles, and inflammatory markers. The strength of our model is its ability to accurately predict CVD risk in patients with prediabetes and diabetes, indicating its significant clinical utility. Importantly, our research underscores the seamless transition from prediabetes to diabetes, highlighting the continuum of risk and the effectiveness of the model in identifying the increasing risk of CVD. The inclusion of variables across a spectrum of health determinants reinforces the comprehensive nature of our nomogram, which extends beyond traditional risk factors and offers a holistic assessment of CVD risk. Our findings have profound clinical implications, providing a tool for the early detection and stratification of CVD risk and facilitating timely interventions that could arrest or reverse the progression of cardiometabolic consequences. Across the continuum of glycemic control from prediabetes to overt diabetes, our models affirm the necessity for proactive health management strategies and demonstrate the potential for individualized patient care under the guidance of robust predictive analytics.

Supplementary Information

Supplementary Information.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-71904-3.

Author contributions

Z.I.: Writing—review and editing, Writing—original draft, Methodology, Formal analysis, Data curation, Conceptualization. S.K.: Writing—review and editing, Writing—original draft, Methodology. H.K.: Writing—review and editing, Writing—original draft, Supervision, Methodology, Formal analysis, Data curation, Conceptualization.

Data availability

The datasets analyzed and generated during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Di Cesare M The heart of the world Glob. Heart 2024 19 11 10.5334/gh.1288 38273998
Di Cesare, M. et al. The heart of the world. Glob. Heart 19, 11. 10.5334/gh.1288 (2024).38273998 10.5334/gh.1288
2. Dal Canto E Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications Eur. J. Prev. Cardiol. 2019 26 25 32 10.1177/2047487319878371 31722562
Dal Canto, E. et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur. J. Prev. Cardiol. 26, 25–32 (2019).31722562 10.1177/2047487319878371
3. Ahmad OS A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease Nat. Commun. 2015 6 7060 10.1038/ncomms8060 26017687
Ahmad, O. S. et al. A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease. Nat. Commun. 6, 7060 (2015).26017687 10.1038/ncomms8060
4. Aldossari KK Prevalence of prediabetes, diabetes, and its associated risk factors among males in Saudi Arabia: A population-based survey J. Diabetes Res. 2018 2018 1 2194604 29850599
Aldossari, K. K. et al. Prevalence of prediabetes, diabetes, and its associated risk factors among males in Saudi Arabia: A population-based survey. J. Diabetes Res. 2018(1), 2194604 (2018).29850599
5. Dagenais GR Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: Results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial J. Am. Coll. Cardiol. 2013 61 702 711 10.1016/j.jacc.2012.11.036 23410541
Dagenais, G. R. et al. Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: Results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial. J. Am. Coll. Cardiol. 61, 702–711 (2013).23410541 10.1016/j.jacc.2012.11.036
6. Shah AD Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 1·9 million people Lancet Diabetes Endocrinol. 2015 3 105 113 10.1016/s2213-8587(14)70219-0 25466521
Shah, A. D. et al. Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 1·9 million people. Lancet Diabetes Endocrinol. 3, 105–113. 10.1016/s2213-8587(14)70219-0 (2015).25466521 10.1016/s2213-8587(14)70219-0
7. Wang Q Gan Z Gao Q Wang M Zhan B The associations of risk of cardiovascular disease with development stages of diabetes in Chinese population: Findings from a retrospective cohort study in QuZhou city BMC Endocr. Disord. 2024 24 18 10.1186/s12902-024-01544-1 38302943
Wang, Q., Gan, Z., Gao, Q., Wang, M. & Zhan, B. The associations of risk of cardiovascular disease with development stages of diabetes in Chinese population: Findings from a retrospective cohort study in QuZhou city. BMC Endocr. Disord. 24, 18 (2024).38302943 10.1186/s12902-024-01544-1
8. Huang Y Cai X Mai W Li M Hu Y Association between prediabetes and risk of cardiovascular disease and all cause mortality: Systematic review and meta-analysis BMJ 2016 355 i5953 10.1136/bmj.i5953 27881363
Huang, Y., Cai, X., Mai, W., Li, M. & Hu, Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: Systematic review and meta-analysis. BMJ 355, i5953. 10.1136/bmj.i5953 (2016).27881363 10.1136/bmj.i5953
9. Collaborators GT Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: A systematic analysis from the Global Burden of Disease Study 2019 Lancet 2021 397 2337 10.1016/S0140-6736(21)01169-7 34051883
Collaborators, G. T. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: A systematic analysis from the Global Burden of Disease Study 2019. Lancet 397, 2337 (2021).34051883 10.1016/S0140-6736(21)01169-7
10. Zhang Y-B Associations of healthy lifestyle and socioeconomic status with mortality and incident cardiovascular disease: Two prospective cohort studies BMJ 2021 373 n604 10.1136/bmj.n604 33853828
Zhang, Y.-B. et al. Associations of healthy lifestyle and socioeconomic status with mortality and incident cardiovascular disease: Two prospective cohort studies. BMJ 373, n604 (2021).33853828 10.1136/bmj.n604
11. Lindley KJ Socioeconomic determinants of health and cardiovascular outcomes in women: JACC review topic of the week J. Am. Coll. Cardiol. 2021 78 1919 1929 10.1016/j.jacc.2021.09.011 34736568
Lindley, K. J. et al. Socioeconomic determinants of health and cardiovascular outcomes in women: JACC review topic of the week. J. Am. Coll. Cardiol. 78, 1919–1929. 10.1016/j.jacc.2021.09.011 (2021).34736568 10.1016/j.jacc.2021.09.011
12. An S Moon S Park SK Association of metabolic comorbidity with myocardial infarction in individuals with a family history of cardiovascular disease: A prospective cohort study BMC Public Health 2022 22 1992 10.1186/s12889-022-14330-2 36316766
An, S., Moon, S. & Park, S. K. Association of metabolic comorbidity with myocardial infarction in individuals with a family history of cardiovascular disease: A prospective cohort study. BMC Public Health 22, 1992. 10.1186/s12889-022-14330-2 (2022).36316766 10.1186/s12889-022-14330-2
13. Cruz-Ávila HA Ramírez-Alatriste F Martínez-García M Hernández-Lemus E Comorbidity patterns in cardiovascular diseases: the role of life-stage and socioeconomic status Front. Cardiovasc. Med. 2024 11 1215458 10.3389/fcvm.2024.1215458 38414921
Cruz-Ávila, H. A., Ramírez-Alatriste, F., Martínez-García, M. & Hernández-Lemus, E. Comorbidity patterns in cardiovascular diseases: the role of life-stage and socioeconomic status. Front. Cardiovasc. Med. 11, 1215458. 10.3389/fcvm.2024.1215458 (2024).38414921 10.3389/fcvm.2024.1215458
14. Kazemi A Comparing the risk of cardiovascular diseases and all-cause mortality in four lifestyles with a combination of high/low physical activity and healthy/unhealthy diet: A prospective cohort study Int. J. Behav. Nutr. Phys. Act. 2022 19 138 10.1186/s12966-022-01374-1 36384713
Kazemi, A. et al. Comparing the risk of cardiovascular diseases and all-cause mortality in four lifestyles with a combination of high/low physical activity and healthy/unhealthy diet: A prospective cohort study. Int. J. Behav. Nutr. Phys. Act. 19, 138. 10.1186/s12966-022-01374-1 (2022).36384713 10.1186/s12966-022-01374-1
15. Kursa MB Rudnicki WR Feature selection with the Boruta package J. Stat. Softw. 2010 36 1 13 10.18637/jss.v036.i11
Kursa, M. B. & Rudnicki, W. R. Feature selection with the Boruta package. J. Stat. Softw. 36, 1–13 (2010).10.18637/jss.v036.i11
16. Kursa MB Jankowski A Rudnicki WR Boruta–A system for feature selection Fund. Inf. 2010 101 271 285
Kursa, M. B., Jankowski, A. & Rudnicki, W. R. Boruta–A system for feature selection. Fund. Inf. 101, 271–285 (2010).
17. Classification and Diagnosis of Diabetes Standards of Medical Care in Diabetes-2019 Diabetes Care 2019 42 S13 s28 10.2337/dc19-S002 30559228
Classification and Diagnosis of Diabetes. Standards of Medical Care in Diabetes-2019. Diabetes Care 42, S13-s28. 10.2337/dc19-S002 (2019).30559228 10.2337/dc19-S002
18. Diagnosis and Classification of Diabetes Standards of Care in Diabetes-2024 Diabetes Care 2024 47 S20 s42 10.2337/dc24-S002 38078589
Diagnosis and Classification of Diabetes. Standards of Care in Diabetes-2024. Diabetes Care 47, S20-s42. 10.2337/dc24-S002 (2024).38078589 10.2337/dc24-S002
19. Institute of Medicine Committee on a National Surveillance System for, C. & Select Chronic, D. in A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases (National Academies Press (US) Copyright © 2011, National Academy of Sciences. (2011).
20. Tucker JM Welk GJ Beyler NK Physical activity in US adults: Compliance with the physical activity guidelines for Americans Am. J. Prev. Med. 2011 40 454 461 10.1016/j.amepre.2010.12.016 21406280
Tucker, J. M., Welk, G. J. & Beyler, N. K. Physical activity in US adults: Compliance with the physical activity guidelines for Americans. Am. J. Prev. Med. 40, 454–461 (2011).21406280 10.1016/j.amepre.2010.12.016
21. Zhang J Multiparametric MRI-based radiomics nomogram for preoperative prediction of lymphovascular invasion and clinical outcomes in patients with breast invasive ductal carcinoma Eur. Radiol. 2022 32 4079 4089 10.1007/s00330-021-08504-6 35050415
Zhang, J. et al. Multiparametric MRI-based radiomics nomogram for preoperative prediction of lymphovascular invasion and clinical outcomes in patients with breast invasive ductal carcinoma. Eur. Radiol. 32, 4079–4089 (2022).35050415 10.1007/s00330-021-08504-6
22. Brannick B Dagogo-Jack S Prediabetes and cardiovascular disease: Pathophysiology and interventions for prevention and risk reduction Endocrinol. Metab. Clin. 2018 47 33 50 10.1016/j.ecl.2017.10.001
Brannick, B. & Dagogo-Jack, S. Prediabetes and cardiovascular disease: Pathophysiology and interventions for prevention and risk reduction. Endocrinol. Metab. Clin. 47, 33–50 (2018).10.1016/j.ecl.2017.10.001
23. Askin L Tanrıverdi O Tibilli H Turkmen S New method improves the evaluation of subclinical left ventricular dysfunction in type 2 diabetes mellitus Arq. Bras. Cardiol. 2019 113 216 217 10.5935/abc.20190164 31483017
Askin, L., Tanrıverdi, O., Tibilli, H. & Turkmen, S. New method improves the evaluation of subclinical left ventricular dysfunction in type 2 diabetes mellitus. Arq. Bras. Cardiol. 113, 216–217. 10.5935/abc.20190164 (2019).31483017 10.5935/abc.20190164
24. Tamang JP Fermented foods in a global age: East meets West Compr. Rev. Food Sci. Food Safe. 2020 19 184 217 10.1111/1541-4337.12520
Tamang, J. P. et al. Fermented foods in a global age: East meets West. Compr. Rev. Food Sci. Food Safe. 19, 184–217 (2020).10.1111/1541-4337.12520
25. Dai X Gakidou E Lopez AD Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action Tob. Control 2022 31 129 137 10.1136/tobaccocontrol-2021-056535 35241576
Dai, X., Gakidou, E. & Lopez, A. D. Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action. Tob. Control 31, 129–137. 10.1136/tobaccocontrol-2021-056535 (2022).35241576 10.1136/tobaccocontrol-2021-056535
26. Song Y Li S He C PPARγ Gene polymorphisms, metabolic disorders, and coronary artery disease Front. Cardiovasc. Med. 2022 9 808929 10.3389/fcvm.2022.808929 35402540
Song, Y., Li, S. & He, C. PPARγ Gene polymorphisms, metabolic disorders, and coronary artery disease. Front. Cardiovasc. Med. 9, 808929 (2022).35402540 10.3389/fcvm.2022.808929
27. Razieh C Differences in the risk of cardiovascular disease across ethnic groups: UK Biobank observational study Nutr. Metab. Cardiovasc. Dis. 2022 32 2594 2602 10.1016/j.numecd.2022.08.002 36064688
Razieh, C. et al. Differences in the risk of cardiovascular disease across ethnic groups: UK Biobank observational study. Nutr. Metab. Cardiovasc. Dis. 32, 2594–2602. 10.1016/j.numecd.2022.08.002 (2022).36064688 10.1016/j.numecd.2022.08.002
28. Chaturvedi N Ethnic differences in cardiovascular disease Heart 2003 89 681 686 10.1136/heart.89.6.681 12748237
Chaturvedi, N. Ethnic differences in cardiovascular disease. Heart 89, 681–686. 10.1136/heart.89.6.681 (2003).12748237 10.1136/heart.89.6.681
29. Segar MW Development and validation of machine learning-based race-specific models to predict 10-year risk of heart failure: A multicohort analysis Circulation 2021 143 2370 2383 10.1161/circulationaha.120.053134 33845593
Segar, M. W. et al. Development and validation of machine learning-based race-specific models to predict 10-year risk of heart failure: A multicohort analysis. Circulation 143, 2370–2383. 10.1161/circulationaha.120.053134 (2021).33845593 10.1161/circulationaha.120.053134
30. O'Donnell CJ Elosua R Cardiovascular risk factors. Insights from Framingham heart study Revista Española de Cardiol. 2008 61 299 310 10.1016/S1885-5857(08)60118-8
O’Donnell, C. J. & Elosua, R. Cardiovascular risk factors. Insights from Framingham heart study. Revista Española de Cardiol. 61, 299–310. 10.1016/S1885-5857(08)60118-8 (2008).10.1016/S1885-5857(08)60118-8
31. Zapata-Arriaza E Development of a risk prediction nomogram for carotid re-stenosis in the one year RECAST registry Eur. J. Vasc. Endovasc. Surg. 2024 10.1016/j.ejvs.2024.05.033 38802040
Zapata-Arriaza, E. et al. Development of a risk prediction nomogram for carotid re-stenosis in the one year RECAST registry. Eur. J. Vasc. Endovasc. Surg.10.1016/j.ejvs.2024.05.033 (2024).38802040 10.1016/j.ejvs.2024.05.033
32. Zhu W Serum level of lactate dehydrogenase is associated with cardiovascular disease risk as determined by the Framingham risk score and arterial stiffness in a health-examined population in China Int. J. Gener. Med. 2022 15 11 17 10.2147/IJGM.S337517
Zhu, W. et al. Serum level of lactate dehydrogenase is associated with cardiovascular disease risk as determined by the Framingham risk score and arterial stiffness in a health-examined population in China. Int. J. Gener. Med. 15, 11–17 (2022).10.2147/IJGM.S337517
33. Parizadeh SM The diagnostic and prognostic value of red cell distribution width in cardiovascular disease; current status and prospective Biofactors 2019 45 507 516 10.1002/biof.1518 31145514
Parizadeh, S. M. et al. The diagnostic and prognostic value of red cell distribution width in cardiovascular disease; current status and prospective. Biofactors 45, 507–516 (2019).31145514 10.1002/biof.1518
34. Ye Z Systemic immune-inflammation index as a potential biomarker of cardiovascular diseases: A systematic review and meta-analysis Front. Cardiovasc. Med. 2022 9 933913 10.3389/fcvm.2022.933913 36003917
Ye, Z. et al. Systemic immune-inflammation index as a potential biomarker of cardiovascular diseases: A systematic review and meta-analysis. Front. Cardiovasc. Med. 9, 933913 (2022).36003917 10.3389/fcvm.2022.933913
35. Candemir M Kiziltunç E Nurkoç S Şahinarslan A Relationship between systemic immune-inflammation index (SII) and the severity of stable coronary artery disease Angiology 2021 72 575 581 10.1177/0003319720987743 33685239
Candemir, M., Kiziltunç, E., Nurkoç, S. & Şahinarslan, A. Relationship between systemic immune-inflammation index (SII) and the severity of stable coronary artery disease. Angiology 72, 575–581. 10.1177/0003319720987743 (2021).33685239 10.1177/0003319720987743
36. Inácio I Cardiovascular risk prediction by the american diabetes association risk-assessment tool and novel and traditional cardiovascular risk factors in young adults with type 1 diabetes Cureus 2022 14 e22574 10.7759/cureus.22574 35371626
Inácio, I. et al. Cardiovascular risk prediction by the american diabetes association risk-assessment tool and novel and traditional cardiovascular risk factors in young adults with type 1 diabetes. Cureus 14, e22574. 10.7759/cureus.22574 (2022).35371626 10.7759/cureus.22574
37. Feingold, K. R. in Endotext (eds K. R. Feingold et al.) (MDText.com, Inc. Copyright © 2000–2024, MDText.com, Inc., 2000).
38. Zhou Y Huang Y Ji X Wang X Shen L Wang Y Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: A meta-analysis J. Clin. Endocrinol. Metab. 2020 105 1670 1681 10.1210/clinem/dgz252
Zhou, Y. et al. Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: A meta-analysis. J. Clin. Endocrinol. Metab. 105, 1670–1681. 10.1210/clinem/dgz252 (2020).10.1210/clinem/dgz252
39. Liao HW Saver JL Wu YL Chen TH Lee M Ovbiagele B Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis BMJ Open 2017 7 e013927 10.1136/bmjopen-2016-013927 28057658
Liao, H. W. et al. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open 7, e013927. 10.1136/bmjopen-2016-013927 (2017).28057658 10.1136/bmjopen-2016-013927
40. Galindo RJ Comparison of the FreeStyle Libre Pro flash continuous glucose monitoring (CGM) system and point-of-care capillary glucose testing in hospitalized patients with type 2 diabetes treated with basal-bolus insulin regimen Diabetes Care 2020 43 2730 2735 10.2337/dc19-2073 32641372
Galindo, R. J. et al. Comparison of the FreeStyle Libre Pro flash continuous glucose monitoring (CGM) system and point-of-care capillary glucose testing in hospitalized patients with type 2 diabetes treated with basal-bolus insulin regimen. Diabetes Care 43, 2730–2735 (2020).32641372 10.2337/dc19-2073
41. Nimri R Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes Nat. Med. 2020 26 1380 1384 10.1038/s41591-020-1045-7 32908282
Nimri, R. et al. Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. Nat. Med. 26, 1380–1384 (2020).32908282 10.1038/s41591-020-1045-7
42. Tyler NS An artificial intelligence decision support system for the management of type 1 diabetes Nat. Metab. 2020 2 612 619 10.1038/s42255-020-0212-y 32694787
Tyler, N. S. et al. An artificial intelligence decision support system for the management of type 1 diabetes. Nat. Metab. 2, 612–619 (2020).32694787 10.1038/s42255-020-0212-y
43. Pontoppidan JRN A multidisciplinary, shared care clinic using personalized medicine and coordinated care in patients with concomitant type 2 diabetes and cardiovascular disease. Protocol and baseline characteristics Prev. Med. Rep. 2024 38 102594 10.1016/j.pmedr.2024.102594 38283962
Pontoppidan, J. R. N. et al. A multidisciplinary, shared care clinic using personalized medicine and coordinated care in patients with concomitant type 2 diabetes and cardiovascular disease. Protocol and baseline characteristics. Prev. Med. Rep. 38, 102594. 10.1016/j.pmedr.2024.102594 (2024).38283962 10.1016/j.pmedr.2024.102594
44. Rippe JM Lifestyle medicine: The health promoting power of daily habits and practices Am. J. Lifestyle Med. 2018 12 499 512 10.1177/1559827618785554 30783405
Rippe, J. M. Lifestyle medicine: The health promoting power of daily habits and practices. Am. J. Lifestyle Med. 12, 499–512. 10.1177/1559827618785554 (2018).30783405 10.1177/1559827618785554
45. Camici GG Liberale L Aging: The next cardiovascular disease? Eur. Heart J. 2017 38 1621 1623 10.1093/eurheartj/ehx239 29447349
Camici, G. G. & Liberale, L. Aging: The next cardiovascular disease?. Eur. Heart J. 38, 1621–1623. 10.1093/eurheartj/ehx239 (2017).29447349 10.1093/eurheartj/ehx239
46. Esmaeili P Roshanravan N Ghaffari S Mesri Alamdari N Asghari-Jafarabadi M Unraveling atherosclerotic cardiovascular disease risk factors through conditional probability analysis with Bayesian networks: Insights from the AZAR cohort study Sci. Rep. 2024 14 4361 10.1038/s41598-024-55141-2 38388574
Esmaeili, P., Roshanravan, N., Ghaffari, S., Mesri Alamdari, N. & Asghari-Jafarabadi, M. Unraveling atherosclerotic cardiovascular disease risk factors through conditional probability analysis with Bayesian networks: Insights from the AZAR cohort study. Sci. Rep. 14, 4361. 10.1038/s41598-024-55141-2 (2024).38388574 10.1038/s41598-024-55141-2
47. Kim KI Risk stratification of cardiovascular disease according to age groups in new prevention guidelines: A review J. Lipid Atheroscler. 2023 12 96 105 10.12997/jla.2023.12.2.96 37265845
Kim, K. I. Risk stratification of cardiovascular disease according to age groups in new prevention guidelines: A review. J. Lipid Atheroscler. 12, 96–105. 10.12997/jla.2023.12.2.96 (2023).37265845 10.12997/jla.2023.12.2.96
48. Hippisley-Cox J Development and validation of a new algorithm for improved cardiovascular risk prediction Nat. Med. 2024 30 1440 1447 10.1038/s41591-024-02905-y 38637635
Hippisley-Cox, J. et al. Development and validation of a new algorithm for improved cardiovascular risk prediction. Nat. Med. 30, 1440–1447. 10.1038/s41591-024-02905-y (2024).38637635 10.1038/s41591-024-02905-y
49. Brown DI Griendling KK Regulation of signal transduction by reactive oxygen species in the cardiovascular system Circ. Res. 2015 116 531 549 10.1161/CIRCRESAHA.116.303584 25634975
Brown, D. I. & Griendling, K. K. Regulation of signal transduction by reactive oxygen species in the cardiovascular system. Circ. Res. 116, 531–549 (2015).25634975 10.1161/CIRCRESAHA.116.303584
50. Hartl FU Cellular homeostasis and aging Annu. Rev. Biochem. 2016 85 1 4 10.1146/annurev-biochem-011116-110806 27050288
Hartl, F. U. Cellular homeostasis and aging. Annu. Rev. Biochem. 85, 1–4 (2016).27050288 10.1146/annurev-biochem-011116-110806
51. Yun MH Changes in regenerative capacity through lifespan Int. J. Mol. Sci. 2015 16 25392 25432 10.3390/ijms161025392 26512653
Yun, M. H. Changes in regenerative capacity through lifespan. Int. J. Mol. Sci. 16, 25392–25432 (2015).26512653 10.3390/ijms161025392
52. Taylor AA Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus Endocrinol. Metab. Clin. 2001 30 983 997 10.1016/S0889-8529(05)70223-1
Taylor, A. A. Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus. Endocrinol. Metab. Clin. 30, 983–997 (2001).10.1016/S0889-8529(05)70223-1
53. Duncan MS Freiberg MS Greevy RA Kundu S Vasan RS Tindle HA Association of smoking cessation with subsequent risk of cardiovascular disease JAMA 2019 322 642 650 10.1001/jama.2019.10298 31429895
Duncan, M. S. et al. Association of smoking cessation with subsequent risk of cardiovascular disease. JAMA 322, 642–650 (2019).31429895 10.1001/jama.2019.10298
54. Athyros VG Katsiki N Doumas M Karagiannis A Mikhailidis DP Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: A narrative review Curr. Med. Res. Opin. 2013 29 1263 1274 10.1185/03007995.2013.827566 23879722
Athyros, V. G., Katsiki, N., Doumas, M., Karagiannis, A. & Mikhailidis, D. P. Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: A narrative review. Curr. Med. Res. Opin. 29, 1263–1274 (2013).23879722 10.1185/03007995.2013.827566
55. Ambrose JA Barua RS The pathophysiology of cigarette smoking and cardiovascular disease: An update J. Am. Coll. Cardiol. 2004 43 1731 1737 10.1016/j.jacc.2003.12.047 15145091
Ambrose, J. A. & Barua, R. S. The pathophysiology of cigarette smoking and cardiovascular disease: An update. J. Am. Coll. Cardiol. 43, 1731–1737 (2004).15145091 10.1016/j.jacc.2003.12.047
56. Li Q Homeostatic dysregulation proceeds in parallel in multiple physiological systems Aging Cell 2015 14 1103 1112 10.1111/acel.12402 26416593
Li, Q. et al. Homeostatic dysregulation proceeds in parallel in multiple physiological systems. Aging Cell 14, 1103–1112 (2015).26416593 10.1111/acel.12402
57. Lippi G Targher G Montagnana M Salvagno GL Zoppini G Guidi GC Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients Archiv. Pathol. Lab. Med. 2009 133 628 632 10.5858/133.4.628
Lippi, G. et al. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Archiv. Pathol. Lab. Med. 133, 628–632 (2009).10.5858/133.4.628
58. Haenggi E Red blood cell distribution width (RDW): A new nutritional biomarker to assess nutritional risk and response to nutritional therapy? Clin. Nutr. 2024 43 575 585 10.1016/j.clnu.2024.01.001 38242035
Haenggi, E. et al. Red blood cell distribution width (RDW): A new nutritional biomarker to assess nutritional risk and response to nutritional therapy?. Clin. Nutr. 43, 575–585 (2024).38242035 10.1016/j.clnu.2024.01.001
59. Joosse H-J In-vitro and in-silico evidence for oxidative stress as drivers for RDW Sci. Rep. 2023 13 9223 10.1038/s41598-023-36514-5 37286717
Joosse, H.-J. et al. In-vitro and in-silico evidence for oxidative stress as drivers for RDW. Sci. Rep. 13, 9223 (2023).37286717 10.1038/s41598-023-36514-5
60. Tenekecioglu E Red blood cell distribution width is associated with myocardial injury in non-ST-elevation acute coronary syndrome Clinics 2015 70 18 23 10.6061/clinics/2015(01)04 25672424
Tenekecioglu, E. et al. Red blood cell distribution width is associated with myocardial injury in non-ST-elevation acute coronary syndrome. Clinics 70, 18–23 (2015).25672424 10.6061/clinics/2015(01)04
61. Li D Association between red cell distribution width–and–albumin ratio and the risk of peripheral artery disease in patients with diabetes Front. Endocrinol. 2024 15 1272573 10.3389/fendo.2024.1272573
Li, D. et al. Association between red cell distribution width–and–albumin ratio and the risk of peripheral artery disease in patients with diabetes. Front. Endocrinol. 15, 1272573 (2024).10.3389/fendo.2024.1272573
62. Korantzopoulos P Kyrlas K Liu T Li G Goudevenos JA Red blood cell distribution width and atrial fibrillation in patients with sick sinus syndrome J. Cardiol. 2016 67 551 554 10.1016/j.jjcc.2015.07.013 26321105
Korantzopoulos, P., Kyrlas, K., Liu, T., Li, G. & Goudevenos, J. A. Red blood cell distribution width and atrial fibrillation in patients with sick sinus syndrome. J. Cardiol. 67, 551–554 (2016).26321105 10.1016/j.jjcc.2015.07.013
63. Tonelli M Sacks F Arnold M Moye L Davis B Pfeffer M Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease Circulation 2008 117 163 168 10.1161/CIRCULATIONAHA.107.727545 18172029
Tonelli, M. et al. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. Circulation 117, 163–168 (2008).18172029 10.1161/CIRCULATIONAHA.107.727545
64. Seo S-G The association between red cell distribution width and incident hypertension in Korean adults Hypertens. Res. 2020 43 55 61 10.1038/s41440-019-0334-3 31551565
Seo, S.-G. et al. The association between red cell distribution width and incident hypertension in Korean adults. Hypertens. Res. 43, 55–61 (2020).31551565 10.1038/s41440-019-0334-3
65. Shen Z Association between red blood cell distribution width and ischemic stroke recurrence in patients with acute ischemic stroke: A 10-years retrospective cohort analysis Aging 2023 15 3052 37053005
Shen, Z. et al. Association between red blood cell distribution width and ischemic stroke recurrence in patients with acute ischemic stroke: A 10-years retrospective cohort analysis. Aging 15, 3052 (2023).37053005
66. Xiao X Associations of lactate dehydrogenase with risk of renal outcomes and cardiovascular mortality in individuals with diabetic kidney disease Diabetes Res. Clin. Pract. 2023 203 110838 10.1016/j.diabres.2023.110838 37478980
Xiao, X. et al. Associations of lactate dehydrogenase with risk of renal outcomes and cardiovascular mortality in individuals with diabetic kidney disease. Diabetes Res. Clin. Pract. 203, 110838 (2023).37478980 10.1016/j.diabres.2023.110838
67. Zhang H High serum lactate dehydrogenase as a predictor of cardiac insufficiency at follow-up in elderly patients with acute myocardial infarction Archiv. Gerontol. Geriatr. 2024 117 105253 10.1016/j.archger.2023.105253
Zhang, H. et al. High serum lactate dehydrogenase as a predictor of cardiac insufficiency at follow-up in elderly patients with acute myocardial infarction. Archiv. Gerontol. Geriatr. 117, 105253 (2024).10.1016/j.archger.2023.105253
68. Dmour HH Khreisat EF Khreisat AF Hasan SA Atoom O Alkhatib AJ Assessment of lactate dehydrogenase levels among diabetic patients treated in the outpatient clinics at King Hussein Medical Center, Royal Medical Services, Jordan Med. Archiv. 2020 74 384 10.5455/medarh.2020.74.384-386
Dmour, H. H. et al. Assessment of lactate dehydrogenase levels among diabetic patients treated in the outpatient clinics at King Hussein Medical Center, Royal Medical Services, Jordan. Med. Archiv. 74, 384 (2020).10.5455/medarh.2020.74.384-386
69. Hsieh Y-S Is the level of serum lactate dehydrogenase a potential biomarker for glucose monitoring with type 2 diabetes mellitus? Front. Endocrinol. 2022 13 1099805 10.3389/fendo.2022.1099805
Hsieh, Y.-S. et al. Is the level of serum lactate dehydrogenase a potential biomarker for glucose monitoring with type 2 diabetes mellitus?. Front. Endocrinol. 13, 1099805 (2022).10.3389/fendo.2022.1099805
70. Kadier K Association of sleep-related disorders with cardiovascular disease among adults in the United States: A cross-sectional study based on national health and nutrition examination survey 2005–2008 Front. Cardiovasc. Med. 2022 9 954238 10.3389/fcvm.2022.954238 35990939
Kadier, K. et al. Association of sleep-related disorders with cardiovascular disease among adults in the United States: A cross-sectional study based on national health and nutrition examination survey 2005–2008. Front. Cardiovasc. Med. 9, 954238 (2022).35990939 10.3389/fcvm.2022.954238
71. Kaneko H Restfulness from sleep and subsequent cardiovascular disease in the general population Sci. Rep. 2020 10 19674 10.1038/s41598-020-76669-z 33184438
Kaneko, H. et al. Restfulness from sleep and subsequent cardiovascular disease in the general population. Sci. Rep. 10, 19674 (2020).33184438 10.1038/s41598-020-76669-z
72. Choi Y Choi JW Association of sleep disturbance with risk of cardiovascular disease and all-cause mortality in patients with new-onset type 2 diabetes: data from the Korean NHIS-HEALS Cardiovasc. Diabetol. 2020 19 1 8 10.1186/s12933-020-01032-5 31910850
Choi, Y. & Choi, J. W. Association of sleep disturbance with risk of cardiovascular disease and all-cause mortality in patients with new-onset type 2 diabetes: data from the Korean NHIS-HEALS. Cardiovasc. Diabetol. 19, 1–8 (2020).31910850 10.1186/s12933-020-01032-5
73. Hu J Sleep patterns and risks of incident cardiovascular disease and mortality among people with type 2 diabetes: A prospective study of the UK Biobank Diabetol. Metab. Syndr. 2024 16 15 10.1186/s13098-024-01261-8 38212811
Hu, J. et al. Sleep patterns and risks of incident cardiovascular disease and mortality among people with type 2 diabetes: A prospective study of the UK Biobank. Diabetol. Metab. Syndr. 16, 15 (2024).38212811 10.1186/s13098-024-01261-8
74. Ravichandran R Gupta L Singh M Nag A Thomas J Panjiyar BK The interplay between sleep disorders and cardiovascular diseases: A systematic review Cureus 2023 15 898
Ravichandran, R. et al. The interplay between sleep disorders and cardiovascular diseases: A systematic review. Cureus 15, 898 (2023).
75. Pan Y Zhou Y Shi X He S Lai W The association between sleep deprivation and the risk of cardiovascular diseases: A systematic meta-analysis Biomed. Rep. 2023 19 1 10 10.3892/br.2023.1660
Pan, Y., Zhou, Y., Shi, X., He, S. & Lai, W. The association between sleep deprivation and the risk of cardiovascular diseases: A systematic meta-analysis. Biomed. Rep. 19, 1–10 (2023).10.3892/br.2023.1660
76. Addo PNO Mundagowa PT Zhao L Kanyangarara M Brown MJ Liu J Associations between sleep duration, sleep disturbance and cardiovascular disease biomarkers among adults in the United States BMC Public Health 2024 24 947 10.1186/s12889-024-18381-5 38566084
Addo, P. N. O. et al. Associations between sleep duration, sleep disturbance and cardiovascular disease biomarkers among adults in the United States. BMC Public Health 24, 947 (2024).38566084 10.1186/s12889-024-18381-5
77. Sehestedt T Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations Hypertens. Res. 2011 34 714 721 10.1038/hr.2011.6 21307869
Sehestedt, T. et al. Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations. Hypertens. Res. 34, 714–721 (2011).21307869 10.1038/hr.2011.6
78. Matheus ASDM Tannus LRM Cobas RA Palma CCS Negrato CA Gomes MDB Impact of diabetes on cardiovascular disease: an update Int. J. Hypertens. 2013 2013 653789 10.1155/2013/653789 23533715
Matheus, A. S. D. M. et al. Impact of diabetes on cardiovascular disease: an update. Int. J. Hypertens. 2013, 653789 (2013).23533715 10.1155/2013/653789
79. Petrie JR Guzik TJ Touyz RM Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms Can. J. Cardiol. 2018 34 575 584 10.1016/j.cjca.2017.12.005 29459239
Petrie, J. R., Guzik, T. J. & Touyz, R. M. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can. J. Cardiol. 34, 575–584 (2018).29459239 10.1016/j.cjca.2017.12.005
80. Huang Q Wu H Wo M Ma J Fei X Song Y Monocyte–lymphocyte ratio is a valuable predictor for diabetic nephropathy in patients with type 2 diabetes Medicine 2020 99 e20190 10.1097/MD.0000000000020190 32384513
Huang, Q. et al. Monocyte–lymphocyte ratio is a valuable predictor for diabetic nephropathy in patients with type 2 diabetes. Medicine 99, e20190 (2020).32384513 10.1097/MD.0000000000020190
81. Zeng J The platelet-to-lymphocyte ratio predicts diabetic retinopathy in type 2 diabetes mellitus Diabetes Metab. Syndr. Obes. Targets Ther. 2022 15 3617 3626 10.2147/DMSO.S378284
Zeng, J. et al. The platelet-to-lymphocyte ratio predicts diabetic retinopathy in type 2 diabetes mellitus. Diabetes Metab. Syndr. Obes. Targets Ther. 15, 3617–3626 (2022).10.2147/DMSO.S378284
82. Kocak MZ Monocyte lymphocyte ratio as a predictor of diabetic kidney injury in type 2 diabetes mellitus; the MADKID study J. Diab. Metab. Disord. 2020 19 997 1002 10.1007/s40200-020-00595-0
Kocak, M. Z. et al. Monocyte lymphocyte ratio as a predictor of diabetic kidney injury in type 2 diabetes mellitus; the MADKID study. J. Diab. Metab. Disord. 19, 997–1002 (2020).10.1007/s40200-020-00595-0
83. Li Z Jian Y Wei Z Association between monocyte to lymphocyte ratio and diabetic foot ulcer in the population of the US with diabetes based on the 1999–2004 National Health and Nutrition Examination Survey data: A retrospective cross-sectional study Front. Endocrinol. 2024 15 1361393 10.3389/fendo.2024.1361393
Li, Z., Jian, Y. & Wei, Z. Association between monocyte to lymphocyte ratio and diabetic foot ulcer in the population of the US with diabetes based on the 1999–2004 National Health and Nutrition Examination Survey data: A retrospective cross-sectional study. Front. Endocrinol. 15, 1361393 (2024).10.3389/fendo.2024.1361393
84. Song F-H A correlation between monocyte to lymphocyte ratio and long-term prognosis in patients with coronary artery disease after PCI Clin. Appl. Thrombosis/Hemostasis 2021 27 1076029621999717 10.1177/1076029621999717
Song, F.-H. et al. A correlation between monocyte to lymphocyte ratio and long-term prognosis in patients with coronary artery disease after PCI. Clin. Appl. Thrombosis/Hemostasis 27, 1076029621999717 (2021).10.1177/1076029621999717
85. Jiang H Yan W-H Li C-J Wang A-P Dou J-T Mu Y-M Elevated white blood cell count is associated with higher risk of glucose metabolism disorders in middle-aged and elderly Chinese people Int. J. Environ. Res. Public Health 2014 11 5497 5509 10.3390/ijerph110505497 24852600
Jiang, H. et al. Elevated white blood cell count is associated with higher risk of glucose metabolism disorders in middle-aged and elderly Chinese people. Int. J. Environ. Res. Public Health 11, 5497–5509 (2014).24852600 10.3390/ijerph110505497
86. Park JM Lee HS Park JY Jung DH Lee JW White blood cell count as a predictor of incident type 2 diabetes mellitus among non-obese adults: A longitudinal 10-year analysis of the Korean genome and epidemiology study J. Inflamm. Res. 2021 14 1235 1242 10.2147/jir.S300026 33833545
Park, J. M., Lee, H. S., Park, J. Y., Jung, D. H. & Lee, J. W. White blood cell count as a predictor of incident type 2 diabetes mellitus among non-obese adults: A longitudinal 10-year analysis of the Korean genome and epidemiology study. J. Inflamm. Res. 14, 1235–1242. 10.2147/jir.S300026 (2021).33833545 10.2147/jir.S300026
87. Zhao Q Liu R Chen H Yang X Dong J Bai M White blood cells and coronary heart disease: A Mendelian randomization study Front. Genet. 2023 14 1127820 10.3389/fgene.2023.1127820 36824433
Zhao, Q. et al. White blood cells and coronary heart disease: A Mendelian randomization study. Front. Genet. 14, 1127820. 10.3389/fgene.2023.1127820 (2023).36824433 10.3389/fgene.2023.1127820
88. Cassano V Mean platelet volume (MPV) as new marker of diabetic macrovascular complications in patients with different glucose homeostasis: Platelets in cardiovascular risk Cardiovasc. Diabetol. 2024 23 89 10.1186/s12933-024-02177-3 38431644
Cassano, V. et al. Mean platelet volume (MPV) as new marker of diabetic macrovascular complications in patients with different glucose homeostasis: Platelets in cardiovascular risk. Cardiovasc. Diabetol. 23, 89 (2024).38431644 10.1186/s12933-024-02177-3
89. Khodadi E Platelet function in cardiovascular disease: Activation of molecules and activation by molecules Cardiovasc. Toxicol. 2020 20 1 10 10.1007/s12012-019-09555-4 31784932
Khodadi, E. Platelet function in cardiovascular disease: Activation of molecules and activation by molecules. Cardiovasc. Toxicol. 20, 1–10 (2020).31784932 10.1007/s12012-019-09555-4
90. de Oliveira CM Relationship between marital status and incidence of type 2 diabetes mellitus in a Brazilian rural population: The Baependi Heart Study PLoS one 2020 15 e0236869 10.1371/journal.pone.0236869 32745127
de Oliveira, C. M. et al. Relationship between marital status and incidence of type 2 diabetes mellitus in a Brazilian rural population: The Baependi Heart Study. PLoS one 15, e0236869 (2020).32745127 10.1371/journal.pone.0236869
91. Kposowa AJ Aly Ezzat D Breault K Diabetes mellitus and marital status: Evidence from the National Longitudinal Mortality Study on the effect of marital dissolution and the death of a spouse Int. J. Gener. Med. 2021 14 1881 1888 10.2147/IJGM.S307436
Kposowa, A. J., Aly Ezzat, D. & Breault, K. Diabetes mellitus and marital status: Evidence from the National Longitudinal Mortality Study on the effect of marital dissolution and the death of a spouse. Int. J. Gener. Med. 14, 1881–1888 (2021).10.2147/IJGM.S307436
92. Wong CW Marital status and risk of cardiovascular diseases: a systematic review and meta-analysis Heart 2018 104 1937 1948 10.1136/heartjnl-2018-313005 29921571
Wong, C. W. et al. Marital status and risk of cardiovascular diseases: a systematic review and meta-analysis. Heart 104, 1937–1948 (2018).29921571 10.1136/heartjnl-2018-313005
93. Manfredini R Marital status, cardiovascular diseases, and cardiovascular risk factors: A review of the evidence J. Women's Health 2017 26 624 632 10.1089/jwh.2016.6103
Manfredini, R. et al. Marital status, cardiovascular diseases, and cardiovascular risk factors: A review of the evidence. J. Women’s Health 26, 624–632 (2017).10.1089/jwh.2016.6103
94. Zhao Z Association of spousal diabetes status and ideal cardiovascular health metrics with risk of incident diabetes among Chinese adults JAMA Netw. Open 2023 6 e2319038 e2319038 10.1001/jamanetworkopen.2023.19038 37351887
Zhao, Z. et al. Association of spousal diabetes status and ideal cardiovascular health metrics with risk of incident diabetes among Chinese adults. JAMA Netw. Open 6, e2319038–e2319038 (2023).37351887 10.1001/jamanetworkopen.2023.19038
95. Kontush A HDL-mediated mechanisms of protection in cardiovascular disease Cardiovasc. Res. 2014 103 341 349 10.1093/cvr/cvu147 24935434
Kontush, A. HDL-mediated mechanisms of protection in cardiovascular disease. Cardiovasc. Res. 103, 341–349 (2014).24935434 10.1093/cvr/cvu147
96. Lewis GF Rader DJ New insights into the regulation of HDL metabolism and reverse cholesterol transport Circul. Res. 2005 96 1221 1232 10.1161/01.RES.0000170946.56981.5c
Lewis, G. F. & Rader, D. J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circul. Res. 96, 1221–1232 (2005).10.1161/01.RES.0000170946.56981.5c
97. Ouimet M Barrett TJ Fisher EA HDL and reverse cholesterol transport: Basic mechanisms and their roles in vascular health and disease Circul. Res. 2019 124 1505 1518 10.1161/CIRCRESAHA.119.312617
Ouimet, M., Barrett, T. J. & Fisher, E. A. HDL and reverse cholesterol transport: Basic mechanisms and their roles in vascular health and disease. Circul. Res. 124, 1505–1518 (2019).10.1161/CIRCRESAHA.119.312617
98. Ansell BJ Navab M Watson KE Fonarow GC Fogelman AM Anti-inflammatory properties of HDL Rev. Endocr. Metab. Disord. 2004 5 351 358 10.1023/B:REMD.0000045107.71895.b2 15486468
Ansell, B. J., Navab, M., Watson, K. E., Fonarow, G. C. & Fogelman, A. M. Anti-inflammatory properties of HDL. Rev. Endocr. Metab. Disord. 5, 351–358 (2004).15486468 10.1023/B:REMD.0000045107.71895.b2
99. Morgantini C Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes Diabetes 2011 60 2617 2623 10.2337/db11-0378 21852676
Morgantini, C. et al. Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes 60, 2617–2623 (2011).21852676 10.2337/db11-0378
100. Cho K-H The current status of research on high-density lipoproteins (HDL): A paradigm shift from HDL quantity to HDL quality and HDL functionality Int. J. Mol. Sci. 2022 23 3967 10.3390/ijms23073967 35409326
Cho, K.-H. The current status of research on high-density lipoproteins (HDL): A paradigm shift from HDL quantity to HDL quality and HDL functionality. Int. J. Mol. Sci. 23, 3967 (2022).35409326 10.3390/ijms23073967
101. Duffy D Rader DJ Update on strategies to increase HDL quantity and function Nat. Rev. Cardiol. 2009 6 455 463 10.1038/nrcardio.2009.94 19488077
Duffy, D. & Rader, D. J. Update on strategies to increase HDL quantity and function. Nat. Rev. Cardiol. 6, 455–463 (2009).19488077 10.1038/nrcardio.2009.94
102. Ferretti G Bacchetti T Nègre-Salvayre A Salvayre R Dousset N Curatola G Structural modifications of HDL and functional consequences Atherosclerosis 2006 184 1 7 10.1016/j.atherosclerosis.2005.08.008 16157342
Ferretti, G. et al. Structural modifications of HDL and functional consequences. Atherosclerosis 184, 1–7 (2006).16157342 10.1016/j.atherosclerosis.2005.08.008
103. Kashyap SR Glycation reduces the stability of ApoAI and increases HDL dysfunction in diet-controlled type 2 diabetes J. Clin. Endocrinol. Metab. 2018 103 388 396 10.1210/jc.2017-01551 29077935
Kashyap, S. R. et al. Glycation reduces the stability of ApoAI and increases HDL dysfunction in diet-controlled type 2 diabetes. J. Clin. Endocrinol. Metab. 103, 388–396 (2018).29077935 10.1210/jc.2017-01551
104. Mora S Cook N Buring JE Ridker PM Lee I-M Physical activity and reduced risk of cardiovascular events: Potential mediating mechanisms Circulation 2007 116 2110 2118 10.1161/CIRCULATIONAHA.107.729939 17967770
Mora, S., Cook, N., Buring, J. E., Ridker, P. M. & Lee, I.-M. Physical activity and reduced risk of cardiovascular events: Potential mediating mechanisms. Circulation 116, 2110–2118 (2007).17967770 10.1161/CIRCULATIONAHA.107.729939
105. Rognmo Ø Cardiovascular risk of high-versus moderate-intensity aerobic exercise in coronary heart disease patients Circulation 2012 126 1436 1440 10.1161/CIRCULATIONAHA.112.123117 22879367
Rognmo, Ø. et al. Cardiovascular risk of high-versus moderate-intensity aerobic exercise in coronary heart disease patients. Circulation 126, 1436–1440 (2012).22879367 10.1161/CIRCULATIONAHA.112.123117
106. Billinger SA Physical activity and exercise recommendations for stroke survivors: A statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke 2014 45 2532 2553 10.1161/STR.0000000000000022 24846875
Billinger, S. A. et al. Physical activity and exercise recommendations for stroke survivors: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 45, 2532–2553 (2014).24846875 10.1161/STR.0000000000000022
107. Pandey A Chawla S Guchhait P Type-2 diabetes: Current understanding and future perspectives IUBMB Life 2015 67 506 513 10.1002/iub.1396 26177573
Pandey, A., Chawla, S. & Guchhait, P. Type-2 diabetes: Current understanding and future perspectives. IUBMB Life 67, 506–513 (2015).26177573 10.1002/iub.1396
108. Phillips SA Mahmoud AM Brown MD Haus JM Exercise interventions and peripheral arterial function: Implications for cardio-metabolic disease Progr. Cardiovasc. Dis. 2015 57 521 534 10.1016/j.pcad.2014.12.005
Phillips, S. A., Mahmoud, A. M., Brown, M. D. & Haus, J. M. Exercise interventions and peripheral arterial function: Implications for cardio-metabolic disease. Progr. Cardiovasc. Dis. 57, 521–534 (2015).10.1016/j.pcad.2014.12.005
109. Fiuza-Luces C Exercise benefits in cardiovascular disease: Beyond attenuation of traditional risk factors Nat. Rev. Cardiol. 2018 15 731 743 10.1038/s41569-018-0065-1 30115967
Fiuza-Luces, C. et al. Exercise benefits in cardiovascular disease: Beyond attenuation of traditional risk factors. Nat. Rev. Cardiol. 15, 731–743 (2018).30115967 10.1038/s41569-018-0065-1
110. Eijsvogels TM Molossi S Lee D-C Emery MS Thompson PD Exercise at the extremes: The amount of exercise to reduce cardiovascular events J. Am. Coll. Cardiol. 2016 67 316 329 10.1016/j.jacc.2015.11.034 26796398
Eijsvogels, T. M., Molossi, S., Lee, D.-C., Emery, M. S. & Thompson, P. D. Exercise at the extremes: The amount of exercise to reduce cardiovascular events. J. Am. Coll. Cardiol. 67, 316–329 (2016).26796398 10.1016/j.jacc.2015.11.034
111. Myers J Exercise and cardiovascular health Circulation 2003 107 e2 e5 10.1161/01.CIR.0000048890.59383.8D 12515760
Myers, J. Exercise and cardiovascular health. Circulation 107, e2–e5 (2003).12515760 10.1161/01.CIR.0000048890.59383.8D
112. McGavock JM Eves ND Mandic S Glenn NM Quinney HA Haykowsky MJ The role of exercise in the treatment of cardiovascular disease associated with type 2 diabetes mellitus Sports Med. 2004 34 27 48 10.2165/00007256-200434010-00004 14715038
McGavock, J. M. et al. The role of exercise in the treatment of cardiovascular disease associated with type 2 diabetes mellitus. Sports Med. 34, 27–48 (2004).14715038 10.2165/00007256-200434010-00004
113. Barton, M. & Cardillo, C. Vol 117, pp 360–363 (Oxford University Press, 2021).
114. GroupD. P. P. R 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study The Lancet 2009 374 1677 1686 10.1016/S0140-6736(09)61457-4
Group & D. P. P. R,. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. The Lancet 374, 1677–1686 (2009).10.1016/S0140-6736(09)61457-4
115. Group, D. P. P. O. S. R. et al. (2013) Long‐term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabetic Medicine 30, 46–55
116. Diabetes Prevention Program Research Group Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study Lancet Diabetes Endocrinol. 2015 3 866 875 10.1016/S2213-8587(15)00291-0 26377054
Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 3, 866–875 (2015).26377054 10.1016/S2213-8587(15)00291-0
117. Chaturvedi N Ethnic differences in cardiovascular disease Heart 2003 89 681 686 10.1136/heart.89.6.681 12748237
Chaturvedi, N. Ethnic differences in cardiovascular disease. Heart 89, 681–686 (2003).12748237 10.1136/heart.89.6.681
118. Ho FK Ethnic differences in cardiovascular risk: Examining differential exposure and susceptibility to risk factors BMC Med. 2022 20 149 10.1186/s12916-022-02337-w 35473626
Ho, F. K. et al. Ethnic differences in cardiovascular risk: Examining differential exposure and susceptibility to risk factors. BMC Med. 20, 149. 10.1186/s12916-022-02337-w (2022).35473626 10.1186/s12916-022-02337-w
